Market Outlook

By 2035, the U.S. Type 1 Diabetes Care Devices Market is projected to reach approximately USD 29.97 billion, expanding at a CAGR of 12.20% during the forecast period 2026–2035. The market is estimated at USD 9.48 billion in 2025, with historical analysis covering 2021 through 2024. Values in this report are expressed in USD billions.

The historical market expanded from approximately USD 6.12 billion in 2021 to USD 8.45 billion in 2024, supported by accelerated continuous glucose monitoring adoption, migration from conventional insulin pumps toward automated insulin delivery systems, wider pediatric access to diabetes technology, improved commercial and government payer coverage, and the growing preference for connected diabetes management. The market reached an estimated USD 6.79 billion in 2022 and USD 7.56 billion in 2023 before advancing to USD 8.45 billion in 2024 and USD 9.48 billion in 2025.

The U.S. Type 1 diabetes care devices market represents one of the most technology-intensive chronic disease management ecosystems in healthcare. Unlike Type 2 diabetes, where therapeutic pathways span lifestyle modification, oral medications, injectables, insulin and increasingly metabolic technologies, Type 1 diabetes requires continuous lifelong insulin replacement and frequent glucose assessment. This makes device reliability, accuracy, interoperability and recurring supply availability clinically critical rather than discretionary.

Approximately 2.1 million people in the United States have diagnosed Type 1 diabetes, including about 1.8 million adults aged 20 years or older and approximately 314,000 children and adolescents younger than 20 years. This relatively concentrated patient population produces disproportionately high device utilization because many individuals consume recurring CGM sensors, pump infusion sets, tubeless insulin pods, reservoirs, test strips, lancets and related supplies throughout the year.

The next phase of market expansion will be driven less by growth in conventional blood glucose meters and standalone insulin pumps and more by the transition toward continuous glucose monitoring, interoperable pumps, hybrid closed-loop systems, automated insulin delivery, compact wearable pumps, longer-duration sensors, smartphone-controlled therapy and algorithmic insulin dosing. The economic value of the market is consequently shifting from individual hardware products toward recurring connected-care ecosystems.

For market-sizing purposes, the U.S. Type 1 Diabetes Care Devices Market includes revenues generated from continuous glucose monitoring hardware and consumables, insulin pumps, patch pumps, infusion supplies, blood glucose monitoring devices and strips, connected insulin delivery products, relevant diabetes-management software and device accessories attributable to Type 1 diabetes management. Pharmaceutical insulin revenue, general-purpose smartphones and consumer wellness devices without a defined diabetes-management function are excluded.

The market’s attractive forecast profile reflects a structural transition from manually coordinated diabetes management toward integrated sensor-driven therapy. As the installed base of CGM and automated insulin delivery users expands, the revenue model becomes increasingly recurring because sensors, infusion components and disposable pods require frequent replacement. This consumable intensity provides manufacturers with higher lifetime patient value and creates substantial competitive incentives to own the broader diabetes technology ecosystem.

 

Introduction

According to the U.S. Type 1 Diabetes Care Devices Market Report, the competitive opportunity is increasingly defined by the ability to reduce the cognitive and clinical burden of daily diabetes management. People living with Type 1 diabetes may need to make dozens of therapy-related decisions each day involving glucose trends, meals, physical activity, insulin dosing, correction doses and hypoglycemia prevention. Technologies that automate a greater portion of these decisions are therefore gaining both clinical and commercial importance.

Historically, Type 1 diabetes management depended heavily on fingerstick glucose testing and multiple daily insulin injections. Modern care increasingly combines continuous glucose information with connected insulin delivery. CGM systems can generate near-continuous glucose data, while automated insulin delivery platforms link compatible CGMs with insulin pumps and dosing algorithms that increase, decrease or suspend insulin delivery in response to sensor information.

The clinical value proposition is increasingly supported by outcomes data. In a multicenter randomized study of a bionic pancreas involving more than 300 participants with Type 1 diabetes, mean HbA1c in the bionic-pancreas group decreased from 7.9% to 7.3% over 13 weeks, while standard-care participants remained at approximately 7.7%. Participants using the automated system gained approximately 2.6 additional hours per day within the target glucose range. Real-world and controlled studies across other automated insulin delivery systems have similarly demonstrated improvements in time in range and reductions in glycemic burden.

These outcomes have important commercial implications. U.S. endocrinologists increasingly evaluate diabetes devices not only according to sensor accuracy or pump specifications but also according to achievable time in range, hypoglycemia protection, setup complexity, interoperability, alarm burden, remote data visibility and patient continuation rates. Payers are similarly interested in whether advanced diabetes technology can reduce severe hypoglycemia, diabetic ketoacidosis, emergency utilization and longer-term complications.

The purchasing pathway is also materially different from conventional hospital medical devices. Most Type 1 diabetes technology purchasing is influenced by commercial insurers, Medicare, Medicaid programs, pharmacy benefit managers, durable medical equipment suppliers, specialty pharmacies and endocrinology practices rather than hospital capital committees. Manufacturers must therefore manage a complex mix of FDA authorization, payer policy, formulary positioning, benefit design, prior authorization, patient affordability and channel fulfillment.

Medicare coverage is particularly relevant to the aging Type 1 diabetes population. CGMs meeting applicable requirements can be covered under the durable medical equipment benefit for eligible beneficiaries, including insulin-treated individuals. Greater coverage consistency has helped extend modern glucose-monitoring technology beyond younger commercially insured populations.

Commercial competition increasingly revolves around platform retention. Once a patient is trained on a CGM-pump ecosystem, therapy familiarity, device data history, clinician workflow and supply continuity can increase switching friction. Manufacturers consequently compete not only for a first device prescription but also for years of recurring sensor, pod, infusion-set and software-related revenue.

From 2026 through 2035, the strongest value creation is expected in automated insulin delivery, tubeless pumps, longer-duration glucose sensing, interoperable systems, personalized dosing algorithms, pediatric technology, simplified device initiation and remote clinical management. Conventional self-monitoring products will remain clinically relevant as backup technologies, but they will account for a declining proportion of total market value.

 

Key Market Drivers: What’s Fueling the U.S. Type 1 Diabetes Care Devices Market Boom?

The most fundamental market driver is the lifelong clinical requirement for insulin and glucose management. Unlike many chronic diseases where device utilization may be episodic, Type 1 diabetes generates continuous demand. Every diagnosed patient represents a potential multi-decade user of glucose monitoring, insulin administration and therapy-support technology.

A second driver is the increasing prevalence of Type 1 diabetes across both pediatric and adult populations. The United States now has an estimated 2.1 million diagnosed individuals with Type 1 diabetes. More than 300,000 are children and adolescents. Growth in the pediatric population is commercially significant because technology adopted during childhood can influence product familiarity and brand preference for many years.

A third major driver is rapid migration toward continuous glucose monitoring. CGM fundamentally changes the diabetes-management workflow by replacing isolated fingerstick readings with glucose trends, rate-of-change information and programmable alerts. For patients at risk of nocturnal hypoglycemia, exercise-related glucose excursions or unpredictable glucose variability, this continuous visibility provides substantial clinical utility.

CGM also creates the data foundation necessary for automated insulin delivery. As a result, the CGM market and insulin pump market are becoming increasingly interconnected. Manufacturers able to establish preferred interoperability relationships or broad compatibility can influence the wider technology ecosystem rather than compete exclusively at an individual-product level.

Automated insulin delivery is becoming the most important premium growth engine. These platforms combine continuous glucose sensing, an insulin pump and algorithmic dosing logic. Real-world evidence involving tens of thousands of Type 1 diabetes users has demonstrated the ability of modern AID systems to achieve meaningful time-in-range outcomes at population scale. A broader real-world evidence base exceeding 100,000 patients has also demonstrated significant improvement in time in range after adoption of automated insulin delivery.

The fourth driver is reduction of treatment burden. Traditional intensive insulin therapy requires carbohydrate estimation, correction calculations, basal adjustments and continuous vigilance. New-generation algorithms are being designed to simplify these processes. Systems requiring fewer configuration parameters or simplified meal announcements may expand pump eligibility among patients previously viewed as poorly suited to technically demanding therapy.

The fifth driver is pediatric adoption. Children with Type 1 diabetes create a particularly strong need for remote glucose visibility, automated low-glucose protection and caregiver connectivity. Parents can benefit from access to glucose information when a child is at school, sleeping, exercising or away from home. Pediatric endocrinology programs therefore represent major adoption nodes for connected CGM and automated insulin delivery technologies.

A sixth driver is reimbursement expansion. Coverage improvements across Medicare, commercial insurance and state Medicaid programs have progressively reduced one of the historical barriers to CGM and pump utilization. The market remains fragmented by payer, benefit structure and product channel, but advanced diabetes technologies are increasingly being considered components of standard intensive insulin management rather than optional upgrades.

Pharmacy-channel migration is another strategically important driver. When diabetes devices can be fulfilled through pharmacy benefits rather than exclusively through traditional durable medical equipment pathways, patient onboarding can become more familiar and potentially faster. Manufacturers are consequently investing heavily in payer contracting, pharmacy access, specialty distribution and benefit verification infrastructure.

A further driver is the increasing importance of measurable glycemic outcomes. Modern diabetes care emphasizes metrics including HbA1c, time in range, time below range, time above range and glucose variability. Devices that can produce clinically meaningful improvement across these measures have a stronger value proposition for endocrinologists, health plans and integrated delivery networks.

Finally, installed-base economics support durable market expansion. CGM sensors, tubeless insulin pods, reservoirs and infusion sets are recurrent-use products. As more patients transition onto these platforms, manufacturers accumulate recurring revenue streams that are less dependent on one-time hardware replacement cycles. This economic structure is one of the reasons diabetes technology remains highly attractive to established medtech companies and specialized innovators.

 

Innovation in Focus: How Manufacturers Are Raising the Bar?

Innovation in the U.S. Type 1 diabetes devices market is moving from individual device performance toward automated therapeutic ecosystems. Sensor accuracy and pump reliability remain foundational requirements, but the competitive frontier increasingly involves how effectively multiple technologies communicate and how little manual intervention is required from the user.

Automated insulin delivery is at the center of this innovation cycle. The first generations of hybrid closed-loop therapy established the clinical viability of connecting CGM readings with insulin delivery. Newer systems are improving algorithm responsiveness, correction behavior, target personalization and ease of setup while reducing the number of calculations required from patients.

The iLet Bionic Pancreas illustrates the move toward simplified automation. Cleared for people aged six years and older with Type 1 diabetes, the platform can be initialized primarily using body weight and relies on automated dosing logic rather than requiring conventional individualized pump settings for every dosing parameter. This model addresses a major historical limitation of insulin pumps: successful use traditionally required substantial education, carbohydrate counting and continued parameter optimization.

Miniaturization is another major innovation direction. Compact pumps and wearable patch systems are reducing the physical burden associated with insulin infusion. Tubeless systems eliminate conventional pump tubing, while smaller durable pumps increase discretion and wearability. The strategic objective is to narrow the convenience gap between multiple daily injections and pump therapy while preserving the clinical advantages of automated delivery.

Interoperability is also reshaping competition. FDA device classifications for integrated continuous glucose monitors, alternate controller-enabled insulin pumps and automated insulin dosing technologies have created a regulatory foundation for modular systems. This allows selected sensors, pumps and algorithms to communicate across manufacturer boundaries when cleared configurations permit it.

Longer-duration glucose sensing represents another major innovation opportunity. Conventional disposable CGMs typically require sensor changes after a defined wear period, generating high recurring consumption but also repeated insertion burden. The Eversense 365 system represents a different approach through a long-duration implantable sensor designed for extended use. Its U.S. clearance in 2024 expanded competition around sensor longevity and may accelerate innovation in implantable and extended-wear monitoring.

Smartphone integration is becoming central to user experience. Patients increasingly expect glucose information, insulin controls, therapy history and alerts to function through familiar consumer interfaces. This integration improves convenience but also introduces new safety considerations involving operating-system changes, wireless connectivity, alarm settings and software updates. FDA safety communications have highlighted the importance of reliable alert delivery in smartphone-compatible diabetes devices.

Cybersecurity and software quality will therefore become more important competitive variables. As insulin dosing becomes software-mediated, seemingly small connectivity or calculation defects can create clinically serious consequences. Manufacturers must invest in software validation, post-market surveillance, human-factors testing, remote-update controls and rapid corrective-action capabilities.

Clinical data platforms represent an additional innovation layer. Endocrinologists increasingly manage patients using uploaded CGM, pump and dosing information rather than relying only on periodic HbA1c values. Platforms that summarize time in range, glucose patterns, insulin utilization and device adherence can improve the efficiency of clinic visits and enable remote intervention.

Artificial intelligence and adaptive analytics are expected to move gradually into these workflows. The near-term commercial opportunity is less about fully autonomous AI replacing clinical judgment and more about prioritizing patients, detecting persistent patterns, simplifying data review and making automated dosing algorithms increasingly adaptive.

Over the forecast period, innovation will converge around a clear objective: reduce the amount of effort required to achieve safer and more stable glycemic control. Companies capable of combining accurate sensing, reliable insulin delivery, intuitive software, interoperable architecture and payer-supported recurring consumables will have the strongest strategic position.

 

Segmentation Insights

The U.S. Type 1 Diabetes Care Devices Market is segmented on the basis of product category, technology type, patient age group, end user, and region.

 

By Product Category

Continuous Glucose Monitoring Systems

Continuous glucose monitoring represents the largest and one of the fastest-expanding product categories. The segment includes disposable sensors, transmitters where required, receivers and integrated software components. CGM is transitioning from an advanced monitoring option toward the primary glucose-management interface for many individuals using intensive insulin therapy.

The segment benefits from an exceptionally strong recurring-revenue model because sensors require regular replacement. Increasing use among children, adults on multiple daily injections, pump users and older Medicare beneficiaries is broadening the addressable patient base. Integration with automated insulin delivery provides an additional competitive advantage because sensor choice can influence compatibility with insulin pumps and dosing algorithms.

Insulin Pumps, Patch Pumps and Infusion Supplies

Insulin pumps remain a major value segment and include conventional durable pumps, wearable patch pumps, disposable pods, infusion sets, reservoirs, cartridges and associated accessories. Revenue is generated both through hardware replacement and recurring disposables.

Tubeless pump systems are gaining importance because they reduce tubing burden and support wearable use. Conventional pumps remain highly relevant, particularly when advanced algorithms, compact form factors and broad CGM interoperability are available. The strongest growth is expected among pumps capable of participating in automated insulin delivery ecosystems.

Blood Glucose Monitoring Systems

Blood glucose meters, test strips and lancets remain clinically important despite CGM expansion. Fingerstick monitoring continues to serve as a backup when CGM data are unavailable, when symptoms do not correspond with sensor readings, during device startup or failure and in patients who cannot access or tolerate CGM.

However, this category is expected to lose market share over the forecast period. Competition is mature, pricing pressure is substantial and testing frequency typically falls when patients transition to non-adjunctive CGM systems. Value creation will increasingly depend on low-cost access, connected meters and backup integration rather than premium standalone hardware.

Connected Insulin Pens and Injection Devices

A substantial Type 1 diabetes population continues to use multiple daily injections rather than pumps. Connected insulin pens, smart pen caps, dose-tracking technologies, pen needles and related injection devices therefore remain commercially significant.

Connected injection systems can record dose timing, reduce forgotten doses and combine insulin history with CGM information. Their strategic role is especially important among patients who want data-driven management but do not want continuous pump attachment. Over time, algorithm-assisted injection guidance may narrow part of the technology gap between multiple daily injection therapy and pump-based management.

Diabetes Data Management and Device Connectivity Solutions

Software-enabled device management is becoming a strategic product layer. These solutions include diabetes data platforms, device-cloud connectivity, remote patient monitoring interfaces, dosing-support software and applications used alongside regulated medical devices.

Direct software revenue remains smaller than recurring sensor and pump consumables, but software strongly influences platform retention. The company controlling the patient interface, clinician dashboard and data history may have greater ability to retain users across successive hardware cycles.

 

By Technology Type

Standalone Monitoring and Manual Therapy Technologies

This category includes conventional glucose meters, standalone CGM used without automated pump integration and manually controlled insulin delivery. It remains an important market because not every patient wants or qualifies for automated therapy.

Its relative market share will decline through 2035 as interoperability increases. Nevertheless, standalone CGM will remain particularly important among multiple daily injection users and individuals who value continuous monitoring without pump therapy.

Sensor-Augmented Pump Technologies

Sensor-augmented pump therapy represents an intermediate stage between conventional pumping and full automated insulin delivery. These systems use CGM information alongside insulin pumps and may provide alerts, low-glucose suspension or other automated safety features.

This category helped establish the clinical foundation for integrated therapy. Market growth will increasingly migrate toward more advanced automated systems, but sensor-augmented functionality remains an important component of the technology installed base.

Automated Insulin Delivery and Hybrid Closed-Loop Systems

Automated insulin delivery is expected to be the fastest-growing technology segment through 2035. These systems integrate CGM data with algorithm-controlled insulin delivery and can automatically alter basal delivery and, depending on the system, deliver correction insulin.

The commercial opportunity is substantial because AID combines high-value hardware, recurring consumables and software. It also increases competitive ecosystem effects: pump selection can influence CGM selection, and CGM compatibility can affect pump adoption.

Clinical evidence showing improved time in range and lower HbA1c is accelerating acceptance. The next major adoption opportunity lies among patients currently using multiple daily injections or non-automated pump therapy.

Connected Injection and Smart Dosing Technologies

Connected injection technologies represent a strategically important alternative to pump therapy. They combine injection delivery with digital dose capture, reminders, CGM data and potentially algorithmic dose recommendations.

Growth is expected among adults who want greater automation but prefer injections and among payers looking for lower-cost technology pathways. The segment could become increasingly important if manufacturers successfully integrate connected pens with real-time glucose information and decision-support software.

Implantable and Extended-Wear Sensing Technologies

Implantable and extended-duration sensors represent a smaller but differentiated technology segment. Longer wear duration can reduce insertion frequency and create an alternative for users dissatisfied with conventional disposable sensor replacement cycles.

The commercial challenge involves balancing insertion requirements, reimbursement, physician workflow and patient preference against the convenience of longer sensor longevity. Successful adoption could establish a premium niche within the broader CGM category.

 

By Patient Age Group

Pediatric Patients Aged 0–13 Years

Pediatric patients represent one of the highest-value technology adoption groups because Type 1 diabetes management affects not only the child but also parents, school personnel and caregivers. Remote glucose sharing, hypoglycemia alerts and automated insulin adjustment can substantially reduce caregiver burden.

The increasing availability of age-appropriate automated systems will support long-term growth. Early device adoption is also strategically important for manufacturers because a positive childhood experience may translate into extended brand familiarity.

Adolescents Aged 14–19 Years

Adolescence is a clinically challenging period because diabetes-management responsibility shifts progressively from parents to the individual. Irregular meals, exercise, school schedules, sleep patterns and behavioral factors can make glycemic control difficult.

Discrete wearable systems, smartphone interfaces and automation are particularly relevant. Manufacturers that simplify daily management while avoiding excessive alarm burden are well positioned in this demographic.

Young Adults Aged 20–39 Years

Young adults represent a major commercial segment because they combine long expected duration of technology use with high familiarity with connected consumer devices. Convenience, discretion, smartphone control, exercise integration and flexible insulin management are important purchasing considerations.

This group is also affected by insurance transitions involving employment, parental insurance expiration and changes in health plans. Continuity of device coverage can therefore have a significant impact on brand retention.

Adults Aged 40–64 Years

Adults aged 40–64 represent a large value pool because many have lived with Type 1 diabetes for decades and increasingly require tighter management of cardiovascular, renal, retinal and neurologic complication risks.

This group generally has high potential for CGM and AID adoption where coverage is available. Reliability, clinical outcomes and integration with endocrinology practices may carry greater weight than novelty alone.

Older Adults Aged 65 Years and Above

The older adult segment is expected to expand materially as people with Type 1 diabetes live longer. Hypoglycemia avoidance becomes especially important because severe events can result in falls, hospitalization and cardiovascular complications.

Medicare CGM coverage and increasing clinician confidence in automated insulin delivery are improving technology access. Simplified interfaces, caregiver data sharing and dependable alarm performance will be critical product requirements for this population.

 

By End User

Homecare and Self-Management

Home-based self-management is the dominant end-use setting. Type 1 diabetes devices are used continuously during normal daily life rather than primarily inside medical facilities. Product success therefore depends heavily on usability, wearability, durability, training requirements and customer support.

The migration toward home-centered management is strengthening demand for remote software updates, automated supply replenishment, telehealth support and connected clinician dashboards.

Endocrinology Clinics and Diabetes Centers

Endocrinology clinics are strategically important because clinicians heavily influence device selection, training and switching. Clinics must manage compatibility, patient education, insurance documentation and interpretation of uploaded device data.

Manufacturers that reduce administrative burden and provide high-quality training can improve prescription conversion. Clinical workflow efficiency is becoming nearly as important as device performance.

Hospitals and Academic Medical Centers

Hospitals represent a smaller direct consumption channel for long-term diabetes devices but remain critical innovation and evidence centers. Academic institutions participate in clinical trials, evaluate new systems and establish protocols that influence broader community adoption.

Hospital interest in continued CGM or insulin pump use during admissions is also increasing, although inpatient management requires specific institutional safety protocols and clinical oversight.

Retail Pharmacies, Specialty Pharmacies and DME Suppliers

Distribution channels play a decisive role in market access. CGMs, pumps and supplies may move through pharmacy benefits, DME benefits or specialized fulfillment pathways depending on the product and payer.

Companies able to simplify benefit verification, prior authorization, shipment and refill continuity gain an important commercial advantage. Supply interruption is particularly serious in Type 1 diabetes because patients cannot simply discontinue insulin-management technology without transitioning to an alternative regimen.

Telehealth and Remote Diabetes Management Providers

Remote diabetes-management platforms are emerging as important partners in longitudinal care. Connected CGM and pump data enable clinicians to review glycemic outcomes between in-person visits.

This model is especially valuable in areas with endocrinologist shortages. Remote care can extend specialist expertise into rural communities and may improve the scalability of advanced diabetes technology.

 

Regional Insights: Where the Market is Growing Fastest

The U.S. Type 1 Diabetes Care Devices Market is geographically divided into the South, Northeast, West and Midwest. Regional differences reflect population size, pediatric diabetes caseload, insurance coverage, Medicaid policy, endocrinologist availability, academic diabetes-center concentration, technology adoption, income distribution, pharmacy access and rurality.

The South represents the largest regional market in 2025, while the West is expected to record the fastest growth through 2035. The Northeast remains an important early-adoption and clinical-research region, while the Midwest provides a substantial installed base of Type 1 diabetes patients across metropolitan and regional health systems.

South

The South accounted for an estimated USD 3.45 billion in 2025, representing approximately 36% of the national market. If current adoption trends continue, the regional market could reach approximately USD 11.20 billion by 2035, supported by an estimated CAGR of around 12.5%.

The region includes Texas, Florida, Georgia, North Carolina, South Carolina, Virginia, Maryland, Delaware, Tennessee, Kentucky, Alabama, Mississippi, Louisiana, Arkansas, Oklahoma, West Virginia and the District of Columbia under the regional framework used for this report.

Texas is one of the most important individual state markets. Its large population and major healthcare hubs in Houston, Dallas-Fort Worth, Austin and San Antonio support substantial pediatric and adult endocrinology capacity. Major academic institutions and children’s hospitals also provide pathways for rapid adoption of advanced CGM and AID systems.

Florida represents another major commercial opportunity. Its combination of population scale and a large older-adult population creates demand across both commercially insured and Medicare beneficiaries. The aging Type 1 diabetes population makes CGM, hypoglycemia protection and simplified automated insulin delivery particularly relevant.

North Carolina has a strong academic and life-sciences ecosystem and benefits from major diabetes programs in the Research Triangle and surrounding metropolitan areas. Georgia, Tennessee and Virginia have expanding health systems and sizable urban populations capable of supporting specialist diabetes care.

Maryland benefits from proximity to federal research infrastructure and sophisticated health systems. The state is also strategically relevant to diabetes device research and technology companies. South Carolina continues to expand specialty-care capacity, although access varies between metropolitan and rural communities.

Alabama, Mississippi, Louisiana, Arkansas, Kentucky, Oklahoma and West Virginia represent important access-driven markets. Advanced diabetes technology penetration may be constrained by endocrinologist shortages, rural geography, insurance variation and affordability. These barriers simultaneously create opportunities for pharmacy-distributed CGM, remote monitoring, simplified AID systems and tele-endocrinology.

Across the South, market success depends heavily on payer contracting and distribution. Manufacturers cannot rely solely on highly specialized academic centers. The long-term growth opportunity will increasingly come from moving advanced technology into community endocrinology, primary-care-supported diabetes management and underserved populations.

West

The West represented an estimated USD 2.05 billion in 2025 and is projected to be the fastest-growing region. At an estimated CAGR of approximately 13.4%, the market could approach USD 7.21 billion by 2035.

The region includes California, Washington, Oregon, Arizona, Nevada, Colorado, Utah, New Mexico, Idaho, Montana, Wyoming, Alaska and Hawaii.

California is the dominant Western state market. Its large population, major pediatric diabetes centers, academic institutions, technology sector and concentration of medtech and digital-health companies make it particularly influential. California provider systems frequently participate in clinical studies and early adoption of CGM, automated insulin delivery and connected diabetes technology.

The state is also commercially important because it contains major diabetes technology companies and a dense ecosystem of engineers, software developers, clinical researchers and venture investors. San Diego and the broader Southern California medtech corridor are particularly relevant to insulin pump development.

Washington and Oregon provide strong adoption environments for connected healthcare and integrated delivery systems. Seattle’s academic ecosystem supports diabetes research, while major regional health networks create opportunities for standardized technology pathways.

Colorado is an important Type 1 diabetes market because of its internationally recognized diabetes research and pediatric care infrastructure. The Denver-Aurora medical ecosystem has played a significant role in clinical studies involving modern insulin-delivery technologies.

Arizona and Nevada are expected to record strong demand growth as their populations expand. An increasing older population will further support CGM and automated insulin delivery demand. Utah also has strong technology adoption and organized health-system infrastructure.

New Mexico, Idaho, Montana, Wyoming and Alaska present smaller absolute markets but significant access challenges. Remote endocrinology, mail-order supplies and cloud-based diabetes management can have disproportionate value in these states because patients may travel substantial distances for specialty care.

Hawaii is a smaller market but has a distinct need for dependable supply logistics and remote specialist support. Across the West, digital infrastructure, technology familiarity and innovation-oriented providers are expected to support above-average adoption through 2035.

Northeast

The Northeast accounted for an estimated USD 2.18 billion in 2025 and could reach approximately USD 6.47 billion by 2035, implying growth of roughly 11.5% annually.

The region includes New York, Pennsylvania, New Jersey, Massachusetts, Connecticut, Rhode Island, Vermont, New Hampshire and Maine. Under some census frameworks Delaware and Maryland are grouped in the South; this report maintains that convention to ensure regional consistency.

New York is the largest Northeast market. New York City contains a dense concentration of academic medical centers, pediatric specialists and adult endocrinology practices capable of adopting high-value Type 1 diabetes technologies. Large health systems also generate substantial real-world clinical experience with CGM and pump platforms.

Massachusetts has strategic importance beyond its population size. Boston’s concentration of academic hospitals, diabetes researchers, medical technology companies and biotechnology organizations makes the state a major innovation center. The presence of diabetes device development activity also strengthens its influence over the competitive landscape.

Pennsylvania combines large metropolitan markets in Philadelphia and Pittsburgh with broad community healthcare networks. New Jersey benefits from high population density, strong commercial insurance coverage in many communities and proximity to pharmaceutical and medtech corporate infrastructure.

Connecticut and Rhode Island are smaller markets but have strong specialist access in major population centers. Vermont, New Hampshire and Maine have smaller patient populations and more geographically dispersed care, increasing the value of remote glucose sharing and telehealth-enabled diabetes management.

The Northeast generally has strong specialist density and high clinical sophistication, which favors advanced AID and CGM technologies. Its primary limitation is slower population growth compared with the South and West. However, high device utilization per patient and strong academic adoption will preserve its premium market position.

Midwest

The Midwest represented an estimated USD 1.80 billion in 2025 and could reach approximately USD 5.07 billion by 2035, reflecting an estimated CAGR of around 10.9%.

The region includes Illinois, Ohio, Michigan, Minnesota, Wisconsin, Indiana, Missouri, Iowa, Kansas, Nebraska, North Dakota and South Dakota.

Illinois is one of the largest Midwestern markets, led by Chicago’s extensive academic and community healthcare infrastructure. Major pediatric centers and endocrinology programs support adoption of CGM and automated insulin delivery.

Ohio has a substantial healthcare ecosystem across Cleveland, Columbus and Cincinnati and benefits from major academic medical centers. Michigan similarly provides a large Type 1 diabetes treatment base through Detroit, Ann Arbor and other regional provider systems.

Minnesota is commercially important because of its deep medical-device ecosystem and strong clinical expertise. The state has historically played an important role in medical technology development and remains highly relevant to diabetes device innovation and manufacturing.

Wisconsin, Indiana and Missouri provide meaningful regional demand across both large health systems and community endocrinology practices. Iowa and Kansas represent smaller but stable markets where technology adoption is increasingly supported by connected care.

Nebraska, North Dakota and South Dakota have lower population densities. These states represent an important use case for remote diabetes management because specialist access can require significant travel. Reliable home-delivered supplies, remote CGM review and virtual endocrinology services can therefore improve technology penetration.

The Midwest is expected to expand more slowly than the West or South but will remain an attractive market because of its large installed base, major academic centers, established payer relationships and strong medical-device expertise.

 

Key Market Players

The U.S. Type 1 Diabetes Care Devices competitive landscape is concentrated around a limited number of scaled CGM and insulin pump manufacturers, surrounded by established blood glucose monitoring companies, injection-device suppliers, data-management firms and a growing group of automated insulin delivery innovators.

Competition is becoming progressively ecosystem-based. Dexcom and Abbott compete strongly in glucose sensing. Insulet, Tandem Diabetes Care, Medtronic and Beta Bionics compete across insulin delivery and automated therapy, while Senseonics differentiates through implantable glucose monitoring. Newer entrants are attempting to disrupt established pump economics through alternative form factors and interoperable architectures.

Some of the key participants relevant to the U.S. Type 1 Diabetes Care Devices industry include Dexcom, Abbott Diabetes Care, Medtronic Diabetes, Insulet Corporation, Tandem Diabetes Care, Beta Bionics, Senseonics Holdings, Ascensia Diabetes Care, LifeScan, Roche Diabetes Care, embecta, Becton Dickinson, Trividia Health, AgaMatrix, Intuity Medical, Glooko, Tidepool, Sequel Med Tech, DEKA Research & Development, Modular Medical, CeQur, Owen Mumford and DarioHealth.

Dexcom has a strong strategic position through integrated CGM and interoperability across multiple insulin-delivery ecosystems. Abbott brings enormous scale in glucose sensing and is increasingly extending its diabetes technology strategy beyond standalone monitoring.

Medtronic remains one of the broadest integrated diabetes-device companies because it combines pumps, sensors and automated insulin delivery. Insulet has transformed the competitive environment through tubeless insulin delivery and automated patch-pump therapy. Tandem Diabetes Care competes through interoperable pump technology, algorithmic control and increasingly compact hardware.

Beta Bionics is strategically differentiated through simplified automated dosing and the iLet platform. Senseonics occupies a distinct position through implantable CGM technology and extended-duration sensing. Sequel Med Tech and DEKA are emerging participants in automated insulin delivery through the twiist platform, while Modular Medical is developing simplified pump solutions intended to broaden pump accessibility.

Competitive share through 2035 will be influenced by sensor accuracy, automated dosing outcomes, device wearability, interoperability, pediatric indications, payer access, channel strategy, supply reliability, customer support, software quality and patient retention.

The market is likely to remain highly competitive despite consolidation because switching decisions are increasingly influenced by ecosystem-level considerations. A manufacturer may gain or lose patients not only because of its own device performance but because a competing ecosystem offers a more attractive combination of CGM, pump, algorithm and smartphone functionality.

 

Recent Developments

Recent developments demonstrate how rapidly the U.S. Type 1 diabetes technology landscape is evolving.

In 2023, the FDA cleared the Beta Bionics iLet ACE Pump and associated dosing-decision software for people aged six years and older with Type 1 diabetes. The system introduced a simplified automated dosing model based largely on body weight at initialization and reduced dependence on conventional pump-setting complexity.

The MiniMed 780G also strengthened advanced hybrid closed-loop competition following U.S. approval for Type 1 diabetes management in people aged seven years and older. Its commercial relevance comes from integrating continuous sensing and automated insulin adjustment within Medtronic’s established diabetes ecosystem.

Tandem Diabetes Care expanded compact pump competition with the Tandem Mobi, an alternate controller-enabled insulin pump designed around a significantly smaller form factor and smartphone-centered operation. The product illustrates the industry’s broader move toward discreet wearable insulin delivery.

In September 2024, the Eversense 365 Continuous Glucose Monitoring System received U.S. clearance, introducing a sensor designed for substantially longer wear than conventional disposable CGM sensors. The development expanded the strategic competition around sensor longevity.

Modular Medical received FDA clearance in September 2024 for its MODD1 Insulin Delivery System, adding another entrant to a pump market historically dominated by relatively few scaled manufacturers.

The twiist insulin-delivery ecosystem continued to progress through FDA clearances in 2025 and 2026. In June 2026, the FDA recorded clearance for an updated twiist Automated Insulin Delivery System, reinforcing the trend toward interoperable automated therapy and increasing competitive pressure in the pump market.

The industry’s growth is accompanied by increasing software-safety requirements. FDA communications and device corrections involving smartphone-compatible diabetes technology and pump software demonstrate that connectivity can create new clinical risks when alarms, glucose information or dosing calculations are disrupted.

These developments indicate that the competitive cycle is accelerating. Product leadership can no longer be defended solely through sensor performance or pump mechanics. Future market winners will require an integrated capability spanning hardware, software, algorithms, interoperability, regulatory compliance, cybersecurity, reimbursement and recurring supply delivery.

 

Conclusion

The U.S. Type 1 Diabetes Care Devices Market Size & Share is projected to expand from USD 9.48 billion in 2025 to approximately USD 29.97 billion by 2035, registering a CAGR of 12.20% during 2026–2035.

The growth opportunity is structurally supported by approximately 2.1 million diagnosed Americans living with Type 1 diabetes, a lifetime requirement for insulin management, increasing pediatric disease burden, broader CGM penetration and rapid migration toward automated insulin delivery.

Continuous glucose monitoring will remain the foundational technology layer, while automated insulin delivery is expected to generate the strongest incremental value growth. Tubeless pumps, compact durable pumps, longer-duration sensors, interoperable systems, connected injection technology and algorithm-based dosing will expand the addressable technology market beyond today’s pump users.

The commercial model is also becoming increasingly attractive because revenue is shifting toward recurring consumables. CGM sensors, disposable pods and infusion supplies generate repeat demand and increase the lifetime economic value of each patient relationship. This recurring model strengthens the importance of patient retention and makes ecosystem compatibility a critical competitive weapon.

Regional opportunity will remain largest in the South due to population scale, with Texas and Florida representing particularly important state markets. The West is expected to grow fastest, led by California and supported by innovation-oriented healthcare systems across Colorado, Washington, Arizona and Utah. The Northeast will remain highly influential in clinical research and early adoption, while the Midwest will provide stable demand and strong medical-device expertise.

For manufacturers and investors, the central strategic question is no longer whether diabetes care will become increasingly connected. The more important questions are which companies will control the sensor-to-insulin-delivery ecosystem, how rapidly automated insulin delivery will penetrate patients currently using injections or non-automated pumps, how reimbursement will influence technology access, and which platforms will achieve the strongest long-term retention.

For health systems, payers and endocrinology networks, device selection will increasingly be determined by measurable outcomes and operational economics. Technologies that improve time in range, reduce severe glucose events, simplify training, minimize clinician workload and maintain reliable supply continuity will be better positioned than devices competing only on technical specifications.

By 2035, Type 1 diabetes management in the United States is expected to be substantially more automated, connected and personalized than it is today. Companies that successfully integrate accurate glucose sensing, dependable insulin delivery, adaptive algorithms, intuitive user experience, strong reimbursement access and clinically credible evidence will define the next decade of the U.S. Type 1 Diabetes Care Devices industry.

 

TABLE OF CONTENT

1. U.S. Type 1 Diabetes Care Devices Market: Market Introduction & Context

1.1. Market Definition
1.2. Scope of the Study
1.3. Research Methodology
1.3.1. Primary Data Collection
1.3.2. Secondary Data Sourcing
1.3.3. External Industry Collaborations
1.3.4. In-House Research Databases
1.3.5. Analytical Frameworks & Forecasting Models
1.3.6. Data Validation and Final Report Publishing
1.4. Key Assumptions
1.5. Market Ecosystem Overview
1.6. Stakeholder Analysis
1.6.1. Continuous Glucose Monitoring Manufacturers
1.6.2. Insulin Pump and Automated Insulin Delivery Manufacturers
1.6.3. Sensor, Infusion Set, Semiconductor and Component Suppliers
1.6.4. Endocrinology Clinics and Diabetes Specialty Centers
1.6.5. Hospitals and Academic Medical Centers
1.6.6. Retail Pharmacies, Specialty Pharmacies and DME Suppliers
1.6.7. Commercial Payers, Medicare, Medicaid and Pharmacy Benefit Managers
1.6.8. Telehealth and Remote Diabetes Management Providers
1.6.9. Patients, Parents and Caregivers
1.6.10. FDA, CMS and Other Regulatory/Policy Stakeholders

What this section provides: This section defines the U.S. Type 1 diabetes care devices market boundary, study scope, methodology, assumptions and stakeholder ecosystem, helping clients understand how CGM, insulin delivery, automated insulin delivery, connected injection and diabetes-management technologies are measured and validated.

2. U.S. Type 1 Diabetes Care Devices Market: Executive Summary

2.1. Key Insights & Market Snapshot
2.2. Analyst Viewpoint
2.3. Market Attractiveness Index
2.4. Historical Market Summary, 2021–2024
2.5. Base Year Market Positioning, 2025
2.6. Forecast Outlook, 2026–2035
2.7. U.S. Type 1 Diabetes Patient Population and Device Adoption Snapshot
2.8. CGM and Insulin Pump Installed-Base Outlook
2.9. Automated Insulin Delivery Adoption Outlook
2.10. High-Growth Opportunity Areas

What this section provides: This section gives decision-makers a concise view of market size, historical performance, forecast growth, Type 1 diabetes device penetration, competitive intensity and priority growth opportunities through 2035.

3. U.S. Type 1 Diabetes Care Devices Market: Market Dynamics & Outlook

3.1. Drivers and Their Impact Analysis
3.1.1. Growing Diagnosed Type 1 Diabetes Population in the U.S.
3.1.2. Rapid Expansion of Continuous Glucose Monitoring Adoption
3.1.3. Migration Toward Automated Insulin Delivery and Hybrid Closed-Loop Therapy
3.1.4. Rising Pediatric and Young-Adult Diabetes Technology Adoption
3.1.5. Expansion of Medicare, Medicaid and Commercial Payer Coverage
3.1.6. Increasing Demand for Connected and Interoperable Diabetes Devices
3.1.7. Growth of Recurring Sensor, Pod and Infusion-Supply Revenue
3.2. Restraints and Their Impact Analysis
3.2.1. High Lifetime Cost of Advanced Diabetes Technology
3.2.2. Insurance Coverage Variability and Prior Authorization Burden
3.2.3. Device Recall, Software and Cybersecurity Risks
3.2.4. Patient Training, Alarm Fatigue and Technology Burden
3.2.5. Supply Continuity and Recurring Consumable Dependence
3.3. Opportunities and Their Impact Analysis
3.3.1. Automated Insulin Delivery Penetration Among Multiple Daily Injection Users
3.3.2. Tubeless and Miniaturized Insulin Pump Expansion
3.3.3. Extended-Wear and Implantable CGM Adoption
3.3.4. Connected Insulin Pens and Smart Dosing Technologies
3.3.5. Pediatric Closed-Loop System Expansion
3.3.6. Remote Diabetes Monitoring and Virtual Endocrinology
3.3.7. Pharmacy-Channel Expansion for Diabetes Devices
3.4. Challenges and Their Impact Analysis
3.4.1. Interoperability and Device Compatibility Complexity
3.4.2. Maintaining Sensor Accuracy Across Diverse Patient Populations
3.4.3. Reimbursement Sustainability and Patient Affordability
3.4.4. Clinical Workforce and Diabetes Educator Constraints
3.5. Patent & Innovation Analysis, 2021–2025
3.6. Diabetes Care Workflow Economics Analysis
3.7. Patient Lifetime Value and Recurring Consumables Economics
3.8. Payer Access and Reimbursement Decision Analysis
3.9. Device Switching and Patient Retention Analysis

What this section provides: This section evaluates the epidemiological, clinical, reimbursement, technological and commercial forces shaping demand and helps clients assess market upside, access barriers, adoption risks and long-term revenue opportunities.

4. U.S. Type 1 Diabetes Care Devices Market: Market Environment & Industry Analysis

4.1. PESTEL Analysis
4.1.1. Political
4.1.2. Economic
4.1.3. Social
4.1.4. Technological
4.1.5. Environmental
4.1.6. Legal
4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Buyers
4.2.3. Bargaining Power of Suppliers
4.2.4. Substitution Risk
4.2.5. Competitive Rivalry
4.3. Pricing Trend Analysis by Region, 2025–2035
4.4. Value Chain & Supply Chain Analysis
4.5. Impact of Digitalization and Connected Diabetes Care
4.6. Automated Insulin Delivery Innovation Landscape
4.7. CGM Sensor Innovation and Wear-Duration Landscape
4.8. FDA Regulatory Framework Analysis
4.9. CMS, Medicare and Medicaid Coverage Landscape
4.10. Commercial Insurance and Pharmacy Benefit Landscape
4.11. Durable Medical Equipment vs. Pharmacy Benefit Channel Analysis
4.12. Import/Export Restrictions & Tariff Impact
4.13. Government Initiatives and Diabetes Public Health Programs
4.14. Impact of Escalating Geopolitical and Supply-Chain Tensions
4.15. Cybersecurity and Connected Medical Device Risk Analysis
4.16. Payer, Formulary and Device Access Decision Framework

What this section provides: This section gives clients a complete assessment of the U.S. Type 1 diabetes device operating environment, including regulation, reimbursement, pricing, supply chain, digital connectivity, technology development and market-access dynamics.

5. U.S. Type 1 Diabetes Care Devices Market – By Product Category

5.1. Overview
5.1.1. Segment Share Analysis, By Product Category, 2025 & 2035 (%)
5.1.2. Continuous Glucose Monitoring Systems
5.1.2.1. CGM Sensors
5.1.2.2. Transmitters
5.1.2.3. Dedicated Receivers
5.1.2.4. Integrated CGM Software and Mobile Applications
5.1.3. Insulin Pumps, Patch Pumps and Infusion Supplies
5.1.3.1. Durable Insulin Pumps
5.1.3.2. Tubeless/Patch Insulin Pumps
5.1.3.3. Infusion Sets
5.1.3.4. Insulin Reservoirs and Cartridges
5.1.3.5. Disposable Pods and Pump Consumables
5.1.4. Blood Glucose Monitoring Systems
5.1.4.1. Blood Glucose Meters
5.1.4.2. Blood Glucose Test Strips
5.1.4.3. Lancets and Lancing Devices
5.1.5. Connected Insulin Pens and Injection Devices
5.1.5.1. Smart Insulin Pens
5.1.5.2. Connected Pen Caps and Dose-Tracking Devices
5.1.5.3. Pen Needles and Related Injection Accessories
5.1.6. Diabetes Data Management and Device Connectivity Solutions
5.1.6.1. Patient-Facing Diabetes Applications
5.1.6.2. Clinician Data Management Platforms
5.1.6.3. Remote Device Monitoring Solutions
5.1.6.4. Dose Decision-Support Software

What this section provides: This section identifies which Type 1 diabetes device categories generate the largest recurring revenue pools and which products are expected to deliver the strongest value growth through 2035.

6. U.S. Type 1 Diabetes Care Devices Market – By Technology Type

6.1. Overview
6.1.1. Segment Share Analysis, By Technology Type, 2025 & 2035 (%)
6.1.2. Standalone Monitoring and Manual Therapy Technologies
6.1.2.1. Conventional Self-Monitoring of Blood Glucose
6.1.2.2. Standalone Continuous Glucose Monitoring
6.1.2.3. Manual Insulin Pump Therapy
6.1.3. Sensor-Augmented Pump Technologies
6.1.3.1. CGM-Integrated Pump Systems
6.1.3.2. Predictive Low-Glucose Suspend Systems
6.1.4. Automated Insulin Delivery and Hybrid Closed-Loop Systems
6.1.4.1. Hybrid Closed-Loop Systems
6.1.4.2. Advanced Hybrid Closed-Loop Systems
6.1.4.3. Algorithm-Based Automated Insulin Delivery
6.1.4.4. Bionic Pancreas Systems
6.1.5. Connected Injection and Smart Dosing Technologies
6.1.5.1. Connected Insulin Pens
6.1.5.2. Dose-Capture Technologies
6.1.5.3. CGM-Integrated Injection Decision Support
6.1.6. Implantable and Extended-Wear Sensing Technologies
6.1.6.1. Extended-Wear Transcutaneous Sensors
6.1.6.2. Implantable Continuous Glucose Sensors

What this section provides: This section evaluates the technology transition from manual diabetes management toward integrated glucose sensing, connected dosing and automated insulin delivery systems.

7. U.S. Type 1 Diabetes Care Devices Market – By Patient Age Group

7.1. Overview
7.1.1. Segment Share Analysis, By Patient Age Group, 2025 & 2035 (%)
7.1.2. Pediatric Patients, 0–13 Years
7.1.2.1. Infants and Preschool-Age Patients
7.1.2.2. School-Age Pediatric Patients
7.1.3. Adolescents, 14–19 Years
7.1.3.1. Early Adolescents
7.1.3.2. Late Adolescents
7.1.4. Young Adults, 20–39 Years
7.1.5. Adults, 40–64 Years
7.1.6. Older Adults, 65 Years and Above

What this section provides: This section analyzes device demand across different Type 1 diabetes age cohorts and identifies how pediatric use, lifestyle requirements, caregiver involvement, Medicare eligibility and hypoglycemia risk affect device adoption.

8. U.S. Type 1 Diabetes Care Devices Market – By End User

8.1. Overview
8.1.1. Segment Share Analysis, By End User, 2025 & 2035 (%)
8.1.2. Homecare and Self-Management
8.1.2.1. Independent Adult Users
8.1.2.2. Parent- and Caregiver-Managed Pediatric Users
8.1.3. Endocrinology Clinics and Diabetes Centers
8.1.3.1. Independent Endocrinology Practices
8.1.3.2. Multispecialty Diabetes Centers
8.1.4. Hospitals and Academic Medical Centers
8.1.4.1. Adult Academic Diabetes Centers
8.1.4.2. Pediatric Diabetes Centers
8.1.5. Retail Pharmacies, Specialty Pharmacies and DME Suppliers
8.1.5.1. Retail Pharmacy Channel
8.1.5.2. Specialty Pharmacy Channel
8.1.5.3. Durable Medical Equipment Suppliers
8.1.6. Telehealth and Remote Diabetes Management Providers
8.1.6.1. Virtual Endocrinology Providers
8.1.6.2. Remote Diabetes Monitoring Platforms

What this section provides: This section explains which patient-care settings, prescriber groups and distribution ecosystems drive device initiation, recurring supplies, patient training and long-term diabetes technology utilization.

9. U.S. Type 1 Diabetes Care Devices Market – By Geography

9.1. Introduction
9.1.1. Segment Share Analysis, By Geography, 2025 & 2035 (%)
9.1.2. Regional Market Size and Forecast, 2021–2035 (US$ Billion)
9.1.3. Regional Type 1 Diabetes Population and Device Adoption Analysis
9.1.4. Regional CGM and Automated Insulin Delivery Penetration Analysis
9.1.5. Regional Endocrinology and Diabetes Center Infrastructure Analysis
9.1.6. Regional Reimbursement, Medicaid and Commercial Payer Dynamics
9.2. West Region
9.2.1. Regional Overview & Trends
9.2.2. West Region Key Manufacturers, Diabetes Centers and Distribution Ecosystem
9.2.3. West Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
9.2.4. West Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
9.2.5. West Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
9.2.6. West Region Market Size and Forecast, By Patient Age Group, 2021–2035 (US$ Billion)
9.2.7. West Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
9.2.8. California
9.2.8.1. Overview
9.2.8.2. California Market Size and Forecast, By Product Category, 2021–2035
9.2.8.3. California Market Size and Forecast, By Technology Type, 2021–2035
9.2.8.4. California Market Size and Forecast, By Patient Age Group, 2021–2035
9.2.8.5. California Market Size and Forecast, By End User, 2021–2035
9.2.9. Washington
9.2.9.1. Overview
9.2.9.2. Washington Market Size and Forecast, By Product Category, 2021–2035
9.2.9.3. Washington Market Size and Forecast, By Technology Type, 2021–2035
9.2.9.4. Washington Market Size and Forecast, By Patient Age Group, 2021–2035
9.2.9.5. Washington Market Size and Forecast, By End User, 2021–2035
9.2.10. Arizona
9.2.10.1. Overview
9.2.10.2. Arizona Market Size and Forecast, By Product Category, 2021–2035
9.2.10.3. Arizona Market Size and Forecast, By Technology Type, 2021–2035
9.2.10.4. Arizona Market Size and Forecast, By Patient Age Group, 2021–2035
9.2.10.5. Arizona Market Size and Forecast, By End User, 2021–2035
9.2.11. Colorado
9.2.11.1. Overview
9.2.11.2. Colorado Market Size and Forecast, By Product Category, 2021–2035
9.2.11.3. Colorado Market Size and Forecast, By Technology Type, 2021–2035
9.2.11.4. Colorado Market Size and Forecast, By Patient Age Group, 2021–2035
9.2.11.5. Colorado Market Size and Forecast, By End User, 2021–2035
9.2.12. Oregon
9.2.12.1. Overview
9.2.12.2. Oregon Market Size and Forecast, By Product Category, 2021–2035
9.2.12.3. Oregon Market Size and Forecast, By Technology Type, 2021–2035
9.2.12.4. Oregon Market Size and Forecast, By Patient Age Group, 2021–2035
9.2.12.5. Oregon Market Size and Forecast, By End User, 2021–2035
9.2.13. Utah
9.2.13.1. Overview
9.2.13.2. Utah Market Size and Forecast, By Product Category, 2021–2035
9.2.13.3. Utah Market Size and Forecast, By Technology Type, 2021–2035
9.2.13.4. Utah Market Size and Forecast, By Patient Age Group, 2021–2035
9.2.13.5. Utah Market Size and Forecast, By End User, 2021–2035
9.2.14. Nevada
9.2.14.1. Overview
9.2.14.2. Nevada Market Size and Forecast, By Product Category, 2021–2035
9.2.14.3. Nevada Market Size and Forecast, By Technology Type, 2021–2035
9.2.14.4. Nevada Market Size and Forecast, By Patient Age Group, 2021–2035
9.2.14.5. Nevada Market Size and Forecast, By End User, 2021–2035
9.2.15. New Mexico
9.2.15.1. Overview
9.2.15.2. New Mexico Market Size and Forecast, By Product Category, 2021–2035
9.2.15.3. New Mexico Market Size and Forecast, By Technology Type, 2021–2035
9.2.15.4. New Mexico Market Size and Forecast, By Patient Age Group, 2021–2035
9.2.15.5. New Mexico Market Size and Forecast, By End User, 2021–2035
9.2.16. Idaho
9.2.16.1. Overview
9.2.16.2. Idaho Market Size and Forecast, By Product Category, 2021–2035
9.2.16.3. Idaho Market Size and Forecast, By Technology Type, 2021–2035
9.2.16.4. Idaho Market Size and Forecast, By Patient Age Group, 2021–2035
9.2.16.5. Idaho Market Size and Forecast, By End User, 2021–2035
9.2.17. Montana
9.2.17.1. Overview
9.2.17.2. Montana Market Size and Forecast, By Product Category, 2021–2035
9.2.17.3. Montana Market Size and Forecast, By Technology Type, 2021–2035
9.2.17.4. Montana Market Size and Forecast, By Patient Age Group, 2021–2035
9.2.17.5. Montana Market Size and Forecast, By End User, 2021–2035
9.2.18. Wyoming
9.2.18.1. Overview
9.2.18.2. Wyoming Market Size and Forecast, By Product Category, 2021–2035
9.2.18.3. Wyoming Market Size and Forecast, By Technology Type, 2021–2035
9.2.18.4. Wyoming Market Size and Forecast, By Patient Age Group, 2021–2035
9.2.18.5. Wyoming Market Size and Forecast, By End User, 2021–2035
9.2.19. Alaska
9.2.19.1. Overview
9.2.19.2. Alaska Market Size and Forecast, By Product Category, 2021–2035
9.2.19.3. Alaska Market Size and Forecast, By Technology Type, 2021–2035
9.2.19.4. Alaska Market Size and Forecast, By Patient Age Group, 2021–2035
9.2.19.5. Alaska Market Size and Forecast, By End User, 2021–2035
9.2.20. Hawaii
9.2.20.1. Overview
9.2.20.2. Hawaii Market Size and Forecast, By Product Category, 2021–2035
9.2.20.3. Hawaii Market Size and Forecast, By Technology Type, 2021–2035
9.2.20.4. Hawaii Market Size and Forecast, By Patient Age Group, 2021–2035
9.2.20.5. Hawaii Market Size and Forecast, By End User, 2021–2035
9.3. Northeast Region
9.3.1. Regional Overview & Trends
9.3.2. Northeast Region Key Manufacturers, Diabetes Centers and Distribution Ecosystem
9.3.3. Northeast Region Market Size and Forecast, By State, 2021–2035
9.3.4. Northeast Region Market Size and Forecast, By Product Category, 2021–2035
9.3.5. Northeast Region Market Size and Forecast, By Technology Type, 2021–2035
9.3.6. Northeast Region Market Size and Forecast, By Patient Age Group, 2021–2035
9.3.7. Northeast Region Market Size and Forecast, By End User, 2021–2035
9.3.8. New York
9.3.8.1. Overview
9.3.8.2. New York Market Size and Forecast, By Product Category, 2021–2035
9.3.8.3. New York Market Size and Forecast, By Technology Type, 2021–2035
9.3.8.4. New York Market Size and Forecast, By Patient Age Group, 2021–2035
9.3.8.5. New York Market Size and Forecast, By End User, 2021–2035
9.3.9. Massachusetts
9.3.9.1. Overview
9.3.9.2. Massachusetts Market Size and Forecast, By Product Category, 2021–2035
9.3.9.3. Massachusetts Market Size and Forecast, By Technology Type, 2021–2035
9.3.9.4. Massachusetts Market Size and Forecast, By Patient Age Group, 2021–2035
9.3.9.5. Massachusetts Market Size and Forecast, By End User, 2021–2035
9.3.10. New Jersey
9.3.10.1. Overview
9.3.10.2. New Jersey Market Size and Forecast, By Product Category, 2021–2035
9.3.10.3. New Jersey Market Size and Forecast, By Technology Type, 2021–2035
9.3.10.4. New Jersey Market Size and Forecast, By Patient Age Group, 2021–2035
9.3.10.5. New Jersey Market Size and Forecast, By End User, 2021–2035
9.3.11. Pennsylvania
9.3.11.1. Overview
9.3.11.2. Pennsylvania Market Size and Forecast, By Product Category, 2021–2035
9.3.11.3. Pennsylvania Market Size and Forecast, By Technology Type, 2021–2035
9.3.11.4. Pennsylvania Market Size and Forecast, By Patient Age Group, 2021–2035
9.3.11.5. Pennsylvania Market Size and Forecast, By End User, 2021–2035
9.3.12. Connecticut
9.3.12.1. Overview
9.3.12.2. Connecticut Market Size and Forecast, By Product Category, 2021–2035
9.3.12.3. Connecticut Market Size and Forecast, By Technology Type, 2021–2035
9.3.12.4. Connecticut Market Size and Forecast, By Patient Age Group, 2021–2035
9.3.12.5. Connecticut Market Size and Forecast, By End User, 2021–2035
9.3.13. Maine
9.3.13.1. Overview
9.3.13.2. Maine Market Size and Forecast, By Product Category, 2021–2035
9.3.13.3. Maine Market Size and Forecast, By Technology Type, 2021–2035
9.3.13.4. Maine Market Size and Forecast, By Patient Age Group, 2021–2035
9.3.13.5. Maine Market Size and Forecast, By End User, 2021–2035
9.3.14. Vermont
9.3.14.1. Overview
9.3.14.2. Vermont Market Size and Forecast, By Product Category, 2021–2035
9.3.14.3. Vermont Market Size and Forecast, By Technology Type, 2021–2035
9.3.14.4. Vermont Market Size and Forecast, By Patient Age Group, 2021–2035
9.3.14.5. Vermont Market Size and Forecast, By End User, 2021–2035
9.3.15. New Hampshire
9.3.15.1. Overview
9.3.15.2. New Hampshire Market Size and Forecast, By Product Category, 2021–2035
9.3.15.3. New Hampshire Market Size and Forecast, By Technology Type, 2021–2035
9.3.15.4. New Hampshire Market Size and Forecast, By Patient Age Group, 2021–2035
9.3.15.5. New Hampshire Market Size and Forecast, By End User, 2021–2035
9.3.16. Rhode Island
9.3.16.1. Overview
9.3.16.2. Rhode Island Market Size and Forecast, By Product Category, 2021–2035
9.3.16.3. Rhode Island Market Size and Forecast, By Technology Type, 2021–2035
9.3.16.4. Rhode Island Market Size and Forecast, By Patient Age Group, 2021–2035
9.3.16.5. Rhode Island Market Size and Forecast, By End User, 2021–2035
9.4. South Region
9.4.1. Regional Overview & Trends
9.4.2. South Region Key Manufacturers, Diabetes Centers and Distribution Ecosystem
9.4.3. South Region Market Size and Forecast, By State, 2021–2035
9.4.4. South Region Market Size and Forecast, By Product Category, 2021–2035
9.4.5. South Region Market Size and Forecast, By Technology Type, 2021–2035
9.4.6. South Region Market Size and Forecast, By Patient Age Group, 2021–2035
9.4.7. South Region Market Size and Forecast, By End User, 2021–2035
9.4.8. Texas
9.4.8.1. Overview
9.4.8.2. Texas Market Size and Forecast, By Product Category, 2021–2035
9.4.8.3. Texas Market Size and Forecast, By Technology Type, 2021–2035
9.4.8.4. Texas Market Size and Forecast, By Patient Age Group, 2021–2035
9.4.8.5. Texas Market Size and Forecast, By End User, 2021–2035
9.4.9. Florida
9.4.9.1. Overview
9.4.9.2. Florida Market Size and Forecast, By Product Category, 2021–2035
9.4.9.3. Florida Market Size and Forecast, By Technology Type, 2021–2035
9.4.9.4. Florida Market Size and Forecast, By Patient Age Group, 2021–2035
9.4.9.5. Florida Market Size and Forecast, By End User, 2021–2035
9.4.10. Georgia
9.4.10.1. Overview
9.4.10.2. Georgia Market Size and Forecast, By Product Category, 2021–2035
9.4.10.3. Georgia Market Size and Forecast, By Technology Type, 2021–2035
9.4.10.4. Georgia Market Size and Forecast, By Patient Age Group, 2021–2035
9.4.10.5. Georgia Market Size and Forecast, By End User, 2021–2035
9.4.11. North Carolina
9.4.11.1. Overview
9.4.11.2. North Carolina Market Size and Forecast, By Product Category, 2021–2035
9.4.11.3. North Carolina Market Size and Forecast, By Technology Type, 2021–2035
9.4.11.4. North Carolina Market Size and Forecast, By Patient Age Group, 2021–2035
9.4.11.5. North Carolina Market Size and Forecast, By End User, 2021–2035
9.4.12. Tennessee
9.4.12.1. Overview
9.4.12.2. Tennessee Market Size and Forecast, By Product Category, 2021–2035
9.4.12.3. Tennessee Market Size and Forecast, By Technology Type, 2021–2035
9.4.12.4. Tennessee Market Size and Forecast, By Patient Age Group, 2021–2035
9.4.12.5. Tennessee Market Size and Forecast, By End User, 2021–2035
9.4.13. South Carolina
9.4.13.1. Overview
9.4.13.2. South Carolina Market Size and Forecast, By Product Category, 2021–2035
9.4.13.3. South Carolina Market Size and Forecast, By Technology Type, 2021–2035
9.4.13.4. South Carolina Market Size and Forecast, By Patient Age Group, 2021–2035
9.4.13.5. South Carolina Market Size and Forecast, By End User, 2021–2035
9.4.14. Alabama
9.4.14.1. Overview
9.4.14.2. Alabama Market Size and Forecast, By Product Category, 2021–2035
9.4.14.3. Alabama Market Size and Forecast, By Technology Type, 2021–2035
9.4.14.4. Alabama Market Size and Forecast, By Patient Age Group, 2021–2035
9.4.14.5. Alabama Market Size and Forecast, By End User, 2021–2035
9.4.15. Mississippi
9.4.15.1. Overview
9.4.15.2. Mississippi Market Size and Forecast, By Product Category, 2021–2035
9.4.15.3. Mississippi Market Size and Forecast, By Technology Type, 2021–2035
9.4.15.4. Mississippi Market Size and Forecast, By Patient Age Group, 2021–2035
9.4.15.5. Mississippi Market Size and Forecast, By End User, 2021–2035
9.4.16. Louisiana
9.4.16.1. Overview
9.4.16.2. Louisiana Market Size and Forecast, By Product Category, 2021–2035
9.4.16.3. Louisiana Market Size and Forecast, By Technology Type, 2021–2035
9.4.16.4. Louisiana Market Size and Forecast, By Patient Age Group, 2021–2035
9.4.16.5. Louisiana Market Size and Forecast, By End User, 2021–2035
9.4.17. Arkansas
9.4.17.1. Overview
9.4.17.2. Arkansas Market Size and Forecast, By Product Category, 2021–2035
9.4.17.3. Arkansas Market Size and Forecast, By Technology Type, 2021–2035
9.4.17.4. Arkansas Market Size and Forecast, By Patient Age Group, 2021–2035
9.4.17.5. Arkansas Market Size and Forecast, By End User, 2021–2035
9.4.18. Kentucky
9.4.18.1. Overview
9.4.18.2. Kentucky Market Size and Forecast, By Product Category, 2021–2035
9.4.18.3. Kentucky Market Size and Forecast, By Technology Type, 2021–2035
9.4.18.4. Kentucky Market Size and Forecast, By Patient Age Group, 2021–2035
9.4.18.5. Kentucky Market Size and Forecast, By End User, 2021–2035
9.4.19. Oklahoma
9.4.19.1. Overview
9.4.19.2. Oklahoma Market Size and Forecast, By Product Category, 2021–2035
9.4.19.3. Oklahoma Market Size and Forecast, By Technology Type, 2021–2035
9.4.19.4. Oklahoma Market Size and Forecast, By Patient Age Group, 2021–2035
9.4.19.5. Oklahoma Market Size and Forecast, By End User, 2021–2035
9.4.20. Virginia
9.4.20.1. Overview
9.4.20.2. Virginia Market Size and Forecast, By Product Category, 2021–2035
9.4.20.3. Virginia Market Size and Forecast, By Technology Type, 2021–2035
9.4.20.4. Virginia Market Size and Forecast, By Patient Age Group, 2021–2035
9.4.20.5. Virginia Market Size and Forecast, By End User, 2021–2035
9.4.21. Maryland
9.4.21.1. Overview
9.4.21.2. Maryland Market Size and Forecast, By Product Category, 2021–2035
9.4.21.3. Maryland Market Size and Forecast, By Technology Type, 2021–2035
9.4.21.4. Maryland Market Size and Forecast, By Patient Age Group, 2021–2035
9.4.21.5. Maryland Market Size and Forecast, By End User, 2021–2035
9.4.22. West Virginia
9.4.22.1. Overview
9.4.22.2. West Virginia Market Size and Forecast, By Product Category, 2021–2035
9.4.22.3. West Virginia Market Size and Forecast, By Technology Type, 2021–2035
9.4.22.4. West Virginia Market Size and Forecast, By Patient Age Group, 2021–2035
9.4.22.5. West Virginia Market Size and Forecast, By End User, 2021–2035
9.4.23. Delaware
9.4.23.1. Overview
9.4.23.2. Delaware Market Size and Forecast, By Product Category, 2021–2035
9.4.23.3. Delaware Market Size and Forecast, By Technology Type, 2021–2035
9.4.23.4. Delaware Market Size and Forecast, By Patient Age Group, 2021–2035
9.4.23.5. Delaware Market Size and Forecast, By End User, 2021–2035
9.4.24. District of Columbia
9.4.24.1. Overview
9.4.24.2. District of Columbia Market Size and Forecast, By Product Category, 2021–2035
9.4.24.3. District of Columbia Market Size and Forecast, By Technology Type, 2021–2035
9.4.24.4. District of Columbia Market Size and Forecast, By Patient Age Group, 2021–2035
9.4.24.5. District of Columbia Market Size and Forecast, By End User, 2021–2035
9.5. Midwest Region
9.5.1. Regional Overview & Trends
9.5.2. Midwest Region Key Manufacturers, Diabetes Centers and Distribution Ecosystem
9.5.3. Midwest Region Market Size and Forecast, By State, 2021–2035
9.5.4. Midwest Region Market Size and Forecast, By Product Category, 2021–2035
9.5.5. Midwest Region Market Size and Forecast, By Technology Type, 2021–2035
9.5.6. Midwest Region Market Size and Forecast, By Patient Age Group, 2021–2035
9.5.7. Midwest Region Market Size and Forecast, By End User, 2021–2035
9.5.8. Illinois
9.5.8.1. Overview
9.5.8.2. Illinois Market Size and Forecast, By Product Category, 2021–2035
9.5.8.3. Illinois Market Size and Forecast, By Technology Type, 2021–2035
9.5.8.4. Illinois Market Size and Forecast, By Patient Age Group, 2021–2035
9.5.8.5. Illinois Market Size and Forecast, By End User, 2021–2035
9.5.9. Ohio
9.5.9.1. Overview
9.5.9.2. Ohio Market Size and Forecast, By Product Category, 2021–2035
9.5.9.3. Ohio Market Size and Forecast, By Technology Type, 2021–2035
9.5.9.4. Ohio Market Size and Forecast, By Patient Age Group, 2021–2035
9.5.9.5. Ohio Market Size and Forecast, By End User, 2021–2035
9.5.10. Michigan
9.5.10.1. Overview
9.5.10.2. Michigan Market Size and Forecast, By Product Category, 2021–2035
9.5.10.3. Michigan Market Size and Forecast, By Technology Type, 2021–2035
9.5.10.4. Michigan Market Size and Forecast, By Patient Age Group, 2021–2035
9.5.10.5. Michigan Market Size and Forecast, By End User, 2021–2035
9.5.11. Minnesota
9.5.11.1. Overview
9.5.11.2. Minnesota Market Size and Forecast, By Product Category, 2021–2035
9.5.11.3. Minnesota Market Size and Forecast, By Technology Type, 2021–2035
9.5.11.4. Minnesota Market Size and Forecast, By Patient Age Group, 2021–2035
9.5.11.5. Minnesota Market Size and Forecast, By End User, 2021–2035
9.5.12. Indiana
9.5.12.1. Overview
9.5.12.2. Indiana Market Size and Forecast, By Product Category, 2021–2035
9.5.12.3. Indiana Market Size and Forecast, By Technology Type, 2021–2035
9.5.12.4. Indiana Market Size and Forecast, By Patient Age Group, 2021–2035
9.5.12.5. Indiana Market Size and Forecast, By End User, 2021–2035
9.5.13. Wisconsin
9.5.13.1. Overview
9.5.13.2. Wisconsin Market Size and Forecast, By Product Category, 2021–2035
9.5.13.3. Wisconsin Market Size and Forecast, By Technology Type, 2021–2035
9.5.13.4. Wisconsin Market Size and Forecast, By Patient Age Group, 2021–2035
9.5.13.5. Wisconsin Market Size and Forecast, By End User, 2021–2035
9.5.14. Missouri
9.5.14.1. Overview
9.5.14.2. Missouri Market Size and Forecast, By Product Category, 2021–2035
9.5.14.3. Missouri Market Size and Forecast, By Technology Type, 2021–2035
9.5.14.4. Missouri Market Size and Forecast, By Patient Age Group, 2021–2035
9.5.14.5. Missouri Market Size and Forecast, By End User, 2021–2035
9.5.15. Iowa
9.5.15.1. Overview
9.5.15.2. Iowa Market Size and Forecast, By Product Category, 2021–2035
9.5.15.3. Iowa Market Size and Forecast, By Technology Type, 2021–2035
9.5.15.4. Iowa Market Size and Forecast, By Patient Age Group, 2021–2035
9.5.15.5. Iowa Market Size and Forecast, By End User, 2021–2035
9.5.16. Kansas
9.5.16.1. Overview
9.5.16.2. Kansas Market Size and Forecast, By Product Category, 2021–2035
9.5.16.3. Kansas Market Size and Forecast, By Technology Type, 2021–2035
9.5.16.4. Kansas Market Size and Forecast, By Patient Age Group, 2021–2035
9.5.16.5. Kansas Market Size and Forecast, By End User, 2021–2035
9.5.17. Nebraska
9.5.17.1. Overview
9.5.17.2. Nebraska Market Size and Forecast, By Product Category, 2021–2035
9.5.17.3. Nebraska Market Size and Forecast, By Technology Type, 2021–2035
9.5.17.4. Nebraska Market Size and Forecast, By Patient Age Group, 2021–2035
9.5.17.5. Nebraska Market Size and Forecast, By End User, 2021–2035
9.5.18. North Dakota
9.5.18.1. Overview
9.5.18.2. North Dakota Market Size and Forecast, By Product Category, 2021–2035
9.5.18.3. North Dakota Market Size and Forecast, By Technology Type, 2021–2035
9.5.18.4. North Dakota Market Size and Forecast, By Patient Age Group, 2021–2035
9.5.18.5. North Dakota Market Size and Forecast, By End User, 2021–2035
9.5.19. South Dakota
9.5.19.1. Overview
9.5.19.2. South Dakota Market Size and Forecast, By Product Category, 2021–2035
9.5.19.3. South Dakota Market Size and Forecast, By Technology Type, 2021–2035
9.5.19.4. South Dakota Market Size and Forecast, By Patient Age Group, 2021–2035
9.5.19.5. South Dakota Market Size and Forecast, By End User, 2021–2035

What this section provides: This section delivers detailed four-region and state-level analysis across all 50 U.S. states, plus the District of Columbia, helping clients identify Type 1 diabetes technology adoption hotspots, CGM and AID growth markets, specialist-care hubs, reimbursement differences and state-level commercial opportunities.

10. U.S. Type 1 Diabetes Care Devices Market: Competitive Landscape & Company Profiles

10.1. Market Share Analysis, 2025
10.2. Competitive Benchmarking by Product Category
10.3. Competitive Benchmarking by CGM Installed Base
10.4. Competitive Benchmarking by Insulin Pump/AID Installed Base
10.5. Company Positioning Matrix
10.5.1. Leaders
10.5.2. Challengers
10.5.3. Innovators
10.5.4. Emerging Players
10.6. Strategic Partnership and Interoperability Matrix
10.7. Company Profiles
10.7.1. Dexcom, Inc.
10.7.2. Abbott Diabetes Care
10.7.3. Medtronic Diabetes
10.7.4. Insulet Corporation
10.7.5. Tandem Diabetes Care, Inc.
10.7.6. Beta Bionics, Inc.
10.7.7. Senseonics Holdings, Inc.
10.7.8. Ascensia Diabetes Care
10.7.9. LifeScan, Inc.
10.7.10. Roche Diabetes Care
10.7.11. embecta Corp.
10.7.12. Becton, Dickinson and Company
10.7.13. Trividia Health, Inc.
10.7.14. AgaMatrix, Inc.
10.7.15. Intuity Medical, Inc.
10.7.16. Glooko, Inc.
10.7.17. Tidepool
10.7.18. Sequel Med Tech, LLC
10.7.19. DEKA Research & Development Corp.
10.7.20. Modular Medical, Inc.
10.7.21. CeQur Corporation
10.7.22. Owen Mumford Ltd.
10.7.23. DarioHealth Corp.

Note: Each company profile will include company overview, U.S. Type 1 diabetes device portfolio, CGM/pump/AID positioning where relevant, U.S. commercialization strategy, financial positioning, installed-base strategy, clinical evidence, FDA regulatory updates, interoperability partnerships, reimbursement strategy and recent developments.

What this section provides: This section provides competitor benchmarking, market-share visibility, CGM and insulin-delivery positioning, interoperability intelligence, innovation direction and strategic assessment of leading and emerging Type 1 diabetes device companies.

11. U.S. Type 1 Diabetes Care Devices Market: Future Market Outlook, 2026–2035

11.1. Scenario Analysis
11.1.1. Optimistic Scenario
11.1.2. Realistic Scenario
11.1.3. Pessimistic Scenario
11.2. Disruptive Technologies Impact
11.2.1. Next-Generation Automated Insulin Delivery
11.2.2. Fully Closed-Loop Insulin Delivery
11.2.3. Tubeless and Miniaturized Pump Platforms
11.2.4. Extended-Wear and Implantable CGM
11.2.5. Adaptive Insulin-Dosing Algorithms
11.2.6. AI-Assisted Diabetes Management
11.2.7. Smart Insulin Pens and Connected Injection Platforms
11.2.8. Smartphone-Controlled Diabetes Devices
11.2.9. Remote Diabetes Monitoring and Virtual Endocrinology
11.3. CGM Penetration Outlook Through 2035
11.4. Automated Insulin Delivery Penetration Outlook Through 2035
11.5. Multiple Daily Injection-to-Pump Conversion Opportunity
11.6. Pediatric Technology Adoption Outlook
11.7. Medicare Type 1 Diabetes Technology Opportunity
11.8. Emerging Business Trends
11.9. Business Opportunities for Startups and Existing Players
11.10. Investment Prioritization Matrix

What this section provides: This section prepares clients for future shifts in glucose sensing, insulin delivery, automation, interoperability and care delivery while identifying market scenarios and investment opportunities through 2035.

12. U.S. Type 1 Diabetes Care Devices Market: Strategic Recommendations

12.1. Recommendations for CGM Manufacturers
12.2. Recommendations for Insulin Pump and AID Manufacturers
12.3. Recommendations for Connected Insulin Delivery Companies
12.4. Recommendations for Endocrinology Practices and Diabetes Centers
12.5. Recommendations for Commercial Payers, Medicare and Medicaid Stakeholders
12.6. Recommendations for Retail Pharmacies, Specialty Pharmacies and DME Suppliers
12.7. Recommendations for Investors and Private Equity Firms
12.8. Recommendations for New Entrants and Startups
12.9. U.S. Go-to-Market Strategy Considerations
12.10. Product Positioning and Portfolio Expansion Guidance
12.11. Interoperability Partnership Strategy
12.12. Payer Contracting and Reimbursement Strategy
12.13. Patient Retention and Recurring Revenue Strategy

What this section provides: This section converts market intelligence into actionable guidance for product strategy, reimbursement, commercialization, channel development, interoperability, investment prioritization and competitive differentiation.

13. U.S. Type 1 Diabetes Care Devices Market: Disclaimer

13.1. Scope Limitation
13.2. Data Use Limitation
13.3. Forecasting Limitation
13.4. Epidemiological Data Limitation
13.5. State-Level Market Estimation Limitation
13.6. Legal Disclaimer
13.7. Third-Party Data Disclaimer

What this section provides: This section clarifies the report’s scope boundaries, forecasting limitations, epidemiological and state-level estimation assumptions, legal terms and restrictions governing interpretation and use of the market intelligence.

 

List of Tables

TABLE 1: List of Data Sources
TABLE 2: U.S. Type 1 Diabetes Care Devices Market: Market Definition and Scope
TABLE 3: U.S. Type 1 Diabetes Care Devices Market: Research Methodology Framework
TABLE 4: U.S. Type 1 Diabetes Care Devices Market: Key Assumptions
TABLE 5: U.S. Type 1 Diabetes Care Devices Market: Market Ecosystem Overview
TABLE 6: U.S. Type 1 Diabetes Care Devices Market: Stakeholder Analysis
TABLE 7: U.S. Type 1 Diabetes Care Devices Market: Executive Summary Snapshot, 2025
TABLE 8: U.S. Type 1 Diabetes Care Devices Market: Analyst Viewpoint Summary
TABLE 9: U.S. Type 1 Diabetes Care Devices Market: Market Attractiveness Index
TABLE 10: U.S. Type 1 Diabetes Care Devices Market: Historical Market Size, 2021–2024 (US$ Billion)
TABLE 11: U.S. Type 1 Diabetes Care Devices Market: Base Year Market Positioning, 2025
TABLE 12: U.S. Type 1 Diabetes Care Devices Market: Forecast Market Size, 2026–2035 (US$ Billion)
TABLE 13: U.S. Type 1 Diabetes Care Devices Market: U.S. Type 1 Diabetes Patient Population and Device Adoption Snapshot
TABLE 14: U.S. Type 1 Diabetes Care Devices Market: CGM and Insulin Pump Installed-Base Outlook
TABLE 15: U.S. Type 1 Diabetes Care Devices Market: High-Growth Opportunity Areas
TABLE 16: U.S. Type 1 Diabetes Care Devices Market: Drivers; Impact Analysis
TABLE 17: U.S. Type 1 Diabetes Care Devices Market: Restraints; Impact Analysis
TABLE 18: U.S. Type 1 Diabetes Care Devices Market: Opportunities; Impact Analysis
TABLE 19: U.S. Type 1 Diabetes Care Devices Market: Challenges; Impact Analysis
TABLE 20: U.S. Type 1 Diabetes Care Devices Market: Patent & Innovation Analysis, 2021–2025
TABLE 21: U.S. Type 1 Diabetes Care Devices Market: Diabetes Care Workflow Economics Matrix
TABLE 22: U.S. Type 1 Diabetes Care Devices Market: Patient Lifetime Value and Recurring Consumables Economics
TABLE 23: U.S. Type 1 Diabetes Care Devices Market: Payer Access and Reimbursement Decision Analysis
TABLE 24: U.S. Type 1 Diabetes Care Devices Market: Device Switching and Patient Retention Analysis
TABLE 25: U.S. Type 1 Diabetes Care Devices Market: Market Dynamics Summary
TABLE 26: U.S. Type 1 Diabetes Care Devices Market: PESTEL Analysis
TABLE 27: U.S. Type 1 Diabetes Care Devices Market: Porter’s Five Forces Analysis
TABLE 28: U.S. Type 1 Diabetes Care Devices Market: Pricing Trend Analysis by Region, 2025–2035
TABLE 29: U.S. Type 1 Diabetes Care Devices Market: Value Chain Analysis
TABLE 30: U.S. Type 1 Diabetes Care Devices Market: Supply Chain Analysis
TABLE 31: U.S. Type 1 Diabetes Care Devices Market: Digitalization and Connected Diabetes Care Impact
TABLE 32: U.S. Type 1 Diabetes Care Devices Market: Automated Insulin Delivery Innovation Landscape
TABLE 33: U.S. Type 1 Diabetes Care Devices Market: CGM Sensor Innovation and Wear-Duration Landscape
TABLE 34: U.S. Type 1 Diabetes Care Devices Market: FDA Regulatory Framework Analysis
TABLE 35: U.S. Type 1 Diabetes Care Devices Market: CMS, Medicare and Medicaid Coverage Landscape
TABLE 36: U.S. Type 1 Diabetes Care Devices Market: Commercial Insurance and Pharmacy Benefit Landscape
TABLE 37: U.S. Type 1 Diabetes Care Devices Market: DME vs. Pharmacy Benefit Channel Analysis
TABLE 38: U.S. Type 1 Diabetes Care Devices Market: Import/Export Restrictions & Tariff Impact
TABLE 39: U.S. Type 1 Diabetes Care Devices Market: Government Initiatives and Diabetes Public Health Programs
TABLE 40: U.S. Type 1 Diabetes Care Devices Market: Geopolitical and Supply-Chain Risk Analysis
TABLE 41: U.S. Type 1 Diabetes Care Devices Market: Cybersecurity and Connected Device Risk Analysis
TABLE 42: U.S. Type 1 Diabetes Care Devices Market: Payer, Formulary and Device Access Decision Framework
TABLE 43: U.S. Type 1 Diabetes Care Devices Market: Product Category Snapshot, 2025
TABLE 44: Segment Dashboard; Definition and Scope, by Product Category
TABLE 45: U.S. Type 1 Diabetes Care Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 46: U.S. Type 1 Diabetes Care Devices Market: Segment Share Analysis, by Product Category, 2025 & 2035 (%)
TABLE 47: Continuous Glucose Monitoring Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 48: Insulin Pumps, Patch Pumps and Infusion Supplies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 49: Blood Glucose Monitoring Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 50: Connected Insulin Pens and Injection Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 51: Diabetes Data Management and Device Connectivity Solutions Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 52: U.S. Type 1 Diabetes Care Devices Market: Product Subsegment Opportunity Matrix
TABLE 53: U.S. Type 1 Diabetes Care Devices Market: Technology Type Snapshot, 2025
TABLE 54: Segment Dashboard; Definition and Scope, by Technology Type
TABLE 55: U.S. Type 1 Diabetes Care Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 56: U.S. Type 1 Diabetes Care Devices Market: Segment Share Analysis, by Technology Type, 2025 & 2035 (%)
TABLE 57: Standalone Monitoring and Manual Therapy Technologies Market Size and Forecast, 2021–2035
TABLE 58: Sensor-Augmented Pump Technologies Market Size and Forecast, 2021–2035
TABLE 59: Automated Insulin Delivery and Hybrid Closed-Loop Systems Market Size and Forecast, 2021–2035
TABLE 60: Connected Injection and Smart Dosing Technologies Market Size and Forecast, 2021–2035
TABLE 61: Implantable and Extended-Wear Sensing Technologies Market Size and Forecast, 2021–2035
TABLE 62: U.S. Type 1 Diabetes Care Devices Market: Technology Adoption and Innovation Matrix
TABLE 63: U.S. Type 1 Diabetes Care Devices Market: Patient Age Group Snapshot, 2025
TABLE 64: Segment Dashboard; Definition and Scope, by Patient Age Group
TABLE 65: U.S. Type 1 Diabetes Care Devices Market, by Patient Age Group, 2021–2035 (US$ Billion)
TABLE 66: U.S. Type 1 Diabetes Care Devices Market: Segment Share Analysis, by Patient Age Group, 2025 & 2035 (%)
TABLE 67: Pediatric Patients, 0–13 Years Market Size and Forecast, 2021–2035
TABLE 68: Adolescents, 14–19 Years Market Size and Forecast, 2021–2035
TABLE 69: Young Adults, 20–39 Years Market Size and Forecast, 2021–2035
TABLE 70: Adults, 40–64 Years Market Size and Forecast, 2021–2035
TABLE 71: Older Adults, 65 Years and Above Market Size and Forecast, 2021–2035
TABLE 72: U.S. Type 1 Diabetes Care Devices Market: Age-Specific Technology Adoption Matrix
TABLE 73: U.S. Type 1 Diabetes Care Devices Market: End User Snapshot, 2025
TABLE 74: Segment Dashboard; Definition and Scope, by End User
TABLE 75: U.S. Type 1 Diabetes Care Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 76: U.S. Type 1 Diabetes Care Devices Market: Segment Share Analysis, by End User, 2025 & 2035 (%)
TABLE 77: Homecare and Self-Management Market Size and Forecast, 2021–2035
TABLE 78: Endocrinology Clinics and Diabetes Centers Market Size and Forecast, 2021–2035
TABLE 79: Hospitals and Academic Medical Centers Market Size and Forecast, 2021–2035
TABLE 80: Retail Pharmacies, Specialty Pharmacies and DME Suppliers Market Size and Forecast, 2021–2035
TABLE 81: Telehealth and Remote Diabetes Management Providers Market Size and Forecast, 2021–2035
TABLE 82: U.S. Type 1 Diabetes Care Devices Market: End-User Access and Adoption Matrix
TABLE 83: U.S. Type 1 Diabetes Care Devices Market: Regional Snapshot, 2025
TABLE 84: Segment Dashboard; Definition and Scope, by Geography
TABLE 85: U.S. Type 1 Diabetes Care Devices Market, by Region, 2021–2035 (US$ Billion)
TABLE 86: U.S. Type 1 Diabetes Care Devices Market: Regional Share Analysis, 2025 & 2035 (%)
TABLE 87: U.S. Type 1 Diabetes Care Devices Market: Type 1 Diabetes Population and Device Adoption, by Region
TABLE 88: U.S. Type 1 Diabetes Care Devices Market: CGM and Automated Insulin Delivery Penetration, by Region
TABLE 89: U.S. Type 1 Diabetes Care Devices Market: Endocrinology and Diabetes Center Infrastructure, by Region
TABLE 90: U.S. Type 1 Diabetes Care Devices Market: Regional Reimbursement and Payer Dynamics
TABLE 91: West Region U.S. Type 1 Diabetes Care Devices Market: Regional Overview and Trends
TABLE 92: West Region U.S. Type 1 Diabetes Care Devices Market: Key Manufacturers, Diabetes Centers and Distribution Ecosystem
TABLE 93: West Region U.S. Type 1 Diabetes Care Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 94: West Region U.S. Type 1 Diabetes Care Devices Market, by Product Category, 2021–2035
TABLE 95: West Region U.S. Type 1 Diabetes Care Devices Market, by Technology Type, 2021–2035
TABLE 96: West Region U.S. Type 1 Diabetes Care Devices Market, by Patient Age Group, 2021–2035
TABLE 97: West Region U.S. Type 1 Diabetes Care Devices Market, by End User, 2021–2035
TABLE 98: California Type 1 Diabetes Care Devices Market Size and Forecast, 2021–2035
TABLE 99: Washington Type 1 Diabetes Care Devices Market Size and Forecast, 2021–2035
TABLE 100: Arizona Type 1 Diabetes Care Devices Market Size and Forecast, 2021–2035
TABLE 101: Colorado Type 1 Diabetes Care Devices Market Size and Forecast, 2021–2035
TABLE 102: Oregon Type 1 Diabetes Care Devices Market Size and Forecast, 2021–2035
TABLE 103: Utah Type 1 Diabetes Care Devices Market Size and Forecast, 2021–2035
TABLE 104: Nevada Type 1 Diabetes Care Devices Market Size and Forecast, 2021–2035
TABLE 105: New Mexico Type 1 Diabetes Care Devices Market Size and Forecast, 2021–2035
TABLE 106: Idaho Type 1 Diabetes Care Devices Market Size and Forecast, 2021–2035
TABLE 107: Montana Type 1 Diabetes Care Devices Market Size and Forecast, 2021–2035
TABLE 108: Wyoming Type 1 Diabetes Care Devices Market Size and Forecast, 2021–2035
TABLE 109: Alaska Type 1 Diabetes Care Devices Market Size and Forecast, 2021–2035
TABLE 110: Hawaii Type 1 Diabetes Care Devices Market Size and Forecast, 2021–2035
TABLE 111: Northeast Region U.S. Type 1 Diabetes Care Devices Market: Regional Overview and Trends
TABLE 112: Northeast Region U.S. Type 1 Diabetes Care Devices Market: Key Manufacturers, Diabetes Centers and Distribution Ecosystem
TABLE 113: Northeast Region U.S. Type 1 Diabetes Care Devices Market, by State, 2021–2035
TABLE 114: Northeast Region U.S. Type 1 Diabetes Care Devices Market, by Product Category, 2021–2035
TABLE 115: Northeast Region U.S. Type 1 Diabetes Care Devices Market, by Technology Type, 2021–2035
TABLE 116: Northeast Region U.S. Type 1 Diabetes Care Devices Market, by Patient Age Group, 2021–2035
TABLE 117: Northeast Region U.S. Type 1 Diabetes Care Devices Market, by End User, 2021–2035
TABLE 118: New York Type 1 Diabetes Care Devices Market Size and Forecast, 2021–2035
TABLE 119: Massachusetts Type 1 Diabetes Care Devices Market Size and Forecast, 2021–2035
TABLE 120: New Jersey Type 1 Diabetes Care Devices Market Size and Forecast, 2021–2035
TABLE 121: Pennsylvania Type 1 Diabetes Care Devices Market Size and Forecast, 2021–2035
TABLE 122: Connecticut Type 1 Diabetes Care Devices Market Size and Forecast, 2021–2035
TABLE 123: Maine Type 1 Diabetes Care Devices Market Size and Forecast, 2021–2035
TABLE 124: Vermont Type 1 Diabetes Care Devices Market Size and Forecast, 2021–2035
TABLE 125: New Hampshire Type 1 Diabetes Care Devices Market Size and Forecast, 2021–2035
TABLE 126: Rhode Island Type 1 Diabetes Care Devices Market Size and Forecast, 2021–2035
TABLE 127: South Region U.S. Type 1 Diabetes Care Devices Market: Regional Overview and Trends
TABLE 128: South Region U.S. Type 1 Diabetes Care Devices Market: Key Manufacturers, Diabetes Centers and Distribution Ecosystem
TABLE 129: South Region U.S. Type 1 Diabetes Care Devices Market, by State, 2021–2035
TABLE 130: South Region U.S. Type 1 Diabetes Care Devices Market, by Product Category, 2021–2035
TABLE 131: South Region U.S. Type 1 Diabetes Care Devices Market, by Technology Type, 2021–2035
TABLE 132: South Region U.S. Type 1 Diabetes Care Devices Market, by Patient Age Group, 2021–2035
TABLE 133: South Region U.S. Type 1 Diabetes Care Devices Market, by End User, 2021–2035
TABLE 134: Texas Type 1 Diabetes Care Devices Market Size and Forecast, 2021–2035
TABLE 135: Florida Type 1 Diabetes Care Devices Market Size and Forecast, 2021–2035
TABLE 136: Georgia Type 1 Diabetes Care Devices Market Size and Forecast, 2021–2035
TABLE 137: North Carolina Type 1 Diabetes Care Devices Market Size and Forecast, 2021–2035
TABLE 138: Tennessee Type 1 Diabetes Care Devices Market Size and Forecast, 2021–2035
TABLE 139: South Carolina Type 1 Diabetes Care Devices Market Size and Forecast, 2021–2035
TABLE 140: Alabama Type 1 Diabetes Care Devices Market Size and Forecast, 2021–2035
TABLE 141: Mississippi Type 1 Diabetes Care Devices Market Size and Forecast, 2021–2035
TABLE 142: Louisiana Type 1 Diabetes Care Devices Market Size and Forecast, 2021–2035
TABLE 143: Arkansas Type 1 Diabetes Care Devices Market Size and Forecast, 2021–2035
TABLE 144: Kentucky Type 1 Diabetes Care Devices Market Size and Forecast, 2021–2035
TABLE 145: Oklahoma Type 1 Diabetes Care Devices Market Size and Forecast, 2021–2035
TABLE 146: Virginia Type 1 Diabetes Care Devices Market Size and Forecast, 2021–2035
TABLE 147: Maryland Type 1 Diabetes Care Devices Market Size and Forecast, 2021–2035
TABLE 148: West Virginia Type 1 Diabetes Care Devices Market Size and Forecast, 2021–2035
TABLE 149: Delaware Type 1 Diabetes Care Devices Market Size and Forecast, 2021–2035
TABLE 150: District of Columbia Type 1 Diabetes Care Devices Market Size and Forecast, 2021–2035
TABLE 151: Midwest Region U.S. Type 1 Diabetes Care Devices Market: Regional Overview and Trends
TABLE 152: Midwest Region U.S. Type 1 Diabetes Care Devices Market: Key Manufacturers, Diabetes Centers and Distribution Ecosystem
TABLE 153: Midwest Region U.S. Type 1 Diabetes Care Devices Market, by State, 2021–2035
TABLE 154: Midwest Region U.S. Type 1 Diabetes Care Devices Market, by Product Category, 2021–2035
TABLE 155: Midwest Region U.S. Type 1 Diabetes Care Devices Market, by Technology Type, 2021–2035
TABLE 156: Midwest Region U.S. Type 1 Diabetes Care Devices Market, by Patient Age Group, 2021–2035
TABLE 157: Midwest Region U.S. Type 1 Diabetes Care Devices Market, by End User, 2021–2035
TABLE 158: Illinois Type 1 Diabetes Care Devices Market Size and Forecast, 2021–2035
TABLE 159: Ohio Type 1 Diabetes Care Devices Market Size and Forecast, 2021–2035
TABLE 160: Michigan Type 1 Diabetes Care Devices Market Size and Forecast, 2021–2035
TABLE 161: Minnesota Type 1 Diabetes Care Devices Market Size and Forecast, 2021–2035
TABLE 162: Indiana Type 1 Diabetes Care Devices Market Size and Forecast, 2021–2035
TABLE 163: Wisconsin Type 1 Diabetes Care Devices Market Size and Forecast, 2021–2035
TABLE 164: Missouri Type 1 Diabetes Care Devices Market Size and Forecast, 2021–2035
TABLE 165: Iowa Type 1 Diabetes Care Devices Market Size and Forecast, 2021–2035
TABLE 166: Kansas Type 1 Diabetes Care Devices Market Size and Forecast, 2021–2035
TABLE 167: Nebraska Type 1 Diabetes Care Devices Market Size and Forecast, 2021–2035
TABLE 168: North Dakota Type 1 Diabetes Care Devices Market Size and Forecast, 2021–2035
TABLE 169: South Dakota Type 1 Diabetes Care Devices Market Size and Forecast, 2021–2035
TABLE 170: U.S. Type 1 Diabetes Care Devices Market: Competitive Landscape Snapshot, 2025
TABLE 171: U.S. Type 1 Diabetes Care Devices Market: Key Company Market Share Analysis, 2025
TABLE 172: U.S. Type 1 Diabetes Care Devices Market: Product Portfolio Benchmarking of Key Players
TABLE 173: U.S. Type 1 Diabetes Care Devices Market: CGM Installed-Base Competitive Benchmarking
TABLE 174: U.S. Type 1 Diabetes Care Devices Market: Insulin Pump and AID Installed-Base Benchmarking
TABLE 175: U.S. Type 1 Diabetes Care Devices Market: Company Positioning Matrix
TABLE 176: U.S. Type 1 Diabetes Care Devices Market: Strategic Partnership and Interoperability Matrix
TABLE 177: U.S. Type 1 Diabetes Care Devices Market: Strategic Developments, Partnerships, M&A and Product Launches
TABLE 178: Dexcom, Inc.: Company Profile
TABLE 179: Abbott Diabetes Care: Company Profile
TABLE 180: Medtronic Diabetes: Company Profile
TABLE 181: Insulet Corporation: Company Profile
TABLE 182: Tandem Diabetes Care, Inc.: Company Profile
TABLE 183: Beta Bionics, Inc.: Company Profile
TABLE 184: Senseonics Holdings, Inc.: Company Profile
TABLE 185: Ascensia Diabetes Care: Company Profile
TABLE 186: LifeScan, Inc.: Company Profile
TABLE 187: Roche Diabetes Care: Company Profile
TABLE 188: embecta Corp.: Company Profile
TABLE 189: Becton, Dickinson and Company: Company Profile
TABLE 190: Trividia Health, Inc.: Company Profile
TABLE 191: AgaMatrix, Inc.: Company Profile
TABLE 192: Intuity Medical, Inc.: Company Profile
TABLE 193: Glooko, Inc.: Company Profile
TABLE 194: Tidepool: Company Profile
TABLE 195: Sequel Med Tech, LLC: Company Profile
TABLE 196: DEKA Research & Development Corp.: Company Profile
TABLE 197: Modular Medical, Inc.: Company Profile
TABLE 198: CeQur Corporation: Company Profile
TABLE 199: Owen Mumford Ltd.: Company Profile
TABLE 200: DarioHealth Corp.: Company Profile
TABLE 201: U.S. Type 1 Diabetes Care Devices Market: Future Market Scenario Analysis, 2026–2035
TABLE 202: U.S. Type 1 Diabetes Care Devices Market: Disruptive Technologies Impact Matrix
TABLE 203: U.S. Type 1 Diabetes Care Devices Market: CGM Penetration Outlook Through 2035
TABLE 204: U.S. Type 1 Diabetes Care Devices Market: Automated Insulin Delivery Penetration Outlook Through 2035
TABLE 205: U.S. Type 1 Diabetes Care Devices Market: Multiple Daily Injection-to-Pump Conversion Opportunity
TABLE 206: U.S. Type 1 Diabetes Care Devices Market: Pediatric Technology Adoption Outlook
TABLE 207: U.S. Type 1 Diabetes Care Devices Market: Medicare Type 1 Diabetes Technology Opportunity
TABLE 208: U.S. Type 1 Diabetes Care Devices Market: Emerging Business Trends
TABLE 209: U.S. Type 1 Diabetes Care Devices Market: Business Opportunities for Startups and Existing Players
TABLE 210: U.S. Type 1 Diabetes Care Devices Market: Investment Prioritization Matrix
TABLE 211: U.S. Type 1 Diabetes Care Devices Market: Strategic Recommendations for CGM Manufacturers
TABLE 212: U.S. Type 1 Diabetes Care Devices Market: Strategic Recommendations for Insulin Pump and AID Manufacturers
TABLE 213: U.S. Type 1 Diabetes Care Devices Market: Strategic Recommendations for Connected Insulin Delivery Companies
TABLE 214: U.S. Type 1 Diabetes Care Devices Market: Strategic Recommendations for Endocrinology Practices and Diabetes Centers
TABLE 215: U.S. Type 1 Diabetes Care Devices Market: Strategic Recommendations for Commercial Payers, Medicare and Medicaid Stakeholders
TABLE 216: U.S. Type 1 Diabetes Care Devices Market: Strategic Recommendations for Retail Pharmacies, Specialty Pharmacies and DME Suppliers
TABLE 217: U.S. Type 1 Diabetes Care Devices Market: Strategic Recommendations for Investors and Private Equity Firms
TABLE 218: U.S. Type 1 Diabetes Care Devices Market: Strategic Recommendations for New Entrants and Startups
TABLE 219: U.S. Type 1 Diabetes Care Devices Market: U.S. Go-to-Market Strategy Considerations
TABLE 220: U.S. Type 1 Diabetes Care Devices Market: Product Positioning and Portfolio Expansion Guidance
TABLE 221: U.S. Type 1 Diabetes Care Devices Market: Interoperability Partnership Strategy
TABLE 222: U.S. Type 1 Diabetes Care Devices Market: Payer Contracting and Reimbursement Strategy
TABLE 223: U.S. Type 1 Diabetes Care Devices Market: Patient Retention and Recurring Revenue Strategy
TABLE 224: U.S. Type 1 Diabetes Care Devices Market: Scope Limitation
TABLE 225: U.S. Type 1 Diabetes Care Devices Market: Data Use Limitation
TABLE 226: U.S. Type 1 Diabetes Care Devices Market: Forecasting Limitation
TABLE 227: U.S. Type 1 Diabetes Care Devices Market: Epidemiological Data Limitation
TABLE 228: U.S. Type 1 Diabetes Care Devices Market: State-Level Market Estimation Limitation
TABLE 229: U.S. Type 1 Diabetes Care Devices Market: Legal Disclaimer
TABLE 230: U.S. Type 1 Diabetes Care Devices Market: Third-Party Data Disclaimer

List of Figures

FIGURE 1: U.S. Type 1 Diabetes Care Devices Market Segmentation
FIGURE 2: Market Research Methodology
FIGURE 3: U.S. Type 1 Diabetes Care Devices Market Ecosystem
FIGURE 4: Market Attractiveness Analysis
FIGURE 5: U.S. Type 1 Diabetes Care Devices Market Size, Historical Trend Analysis, 2021–2024 (US$ Billion)
FIGURE 6: U.S. Type 1 Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2026–2035 (US$ Billion)
FIGURE 7: U.S. Type 1 Diabetes Care Devices Market Year-wise Growth Curve, 2021–2035
FIGURE 8: U.S. Type 1 Diabetes Patient Population and Device Adoption Snapshot
FIGURE 9: CGM and Insulin Pump Installed-Base Outlook
FIGURE 10: U.S. Type 1 Diabetes Care Devices Market Dynamics
FIGURE 11: Market Drivers Impact Analysis
FIGURE 12: Market Restraints Impact Analysis
FIGURE 13: Market Opportunities Impact Analysis
FIGURE 14: Market Challenges Impact Analysis
FIGURE 15: Innovation & Patent Landscape, 2021–2025
FIGURE 16: Diabetes Care Workflow Economics Framework
FIGURE 17: Patient Lifetime Value and Recurring Consumables Economics Framework
FIGURE 18: Payer Access, Device Switching and Patient Retention Framework
FIGURE 19: PESTEL Analysis
FIGURE 20: Porter’s Five Forces Analysis
FIGURE 21: Value Chain Analysis
FIGURE 22: Supply Chain Analysis
FIGURE 23: Regional Pricing Trend Analysis, 2025–2035
FIGURE 24: Digitalization and Connected Diabetes Care Landscape
FIGURE 25: Automated Insulin Delivery Innovation Landscape
FIGURE 26: CGM Sensor Innovation and Wear-Duration Landscape
FIGURE 27: FDA Regulatory and Reimbursement Landscape
FIGURE 28: DME, Pharmacy and Payer Access Channel Landscape
FIGURE 29: Connected Diabetes Device Cybersecurity Risk Framework
FIGURE 30: Product Category Segment Market Share Analysis, 2025 & 2035
FIGURE 31: Product Category Segment Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 32: Continuous Glucose Monitoring Systems Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 33: Insulin Pumps, Patch Pumps and Infusion Supplies Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 34: Blood Glucose Monitoring Systems Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 35: Connected Insulin Pens and Injection Devices Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 36: Diabetes Data Management and Device Connectivity Solutions Market Size Forecast, 2021–2035
FIGURE 37: Technology Type Segment Market Share Analysis, 2025 & 2035
FIGURE 38: Technology Type Segment Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 39: Standalone Monitoring and Manual Therapy Technologies Market Trend, 2021–2035
FIGURE 40: Sensor-Augmented Pump Technologies Market Trend, 2021–2035
FIGURE 41: Automated Insulin Delivery and Hybrid Closed-Loop Systems Market Trend, 2021–2035
FIGURE 42: Connected Injection and Smart Dosing Technologies Market Trend, 2021–2035
FIGURE 43: Implantable and Extended-Wear Sensing Technologies Market Trend, 2021–2035
FIGURE 44: Patient Age Group Segment Market Share Analysis, 2025 & 2035
FIGURE 45: Patient Age Group Segment Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 46: Pediatric Patients, 0–13 Years Market Trend, 2021–2035
FIGURE 47: Adolescents, 14–19 Years Market Trend, 2021–2035
FIGURE 48: Young Adults, 20–39 Years Market Trend, 2021–2035
FIGURE 49: Adults, 40–64 Years Market Trend, 2021–2035
FIGURE 50: Older Adults, 65 Years and Above Market Trend, 2021–2035
FIGURE 51: End User Segment Market Share Analysis, 2025 & 2035
FIGURE 52: End User Segment Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 53: Homecare and Self-Management Market Trend, 2021–2035
FIGURE 54: Endocrinology Clinics and Diabetes Centers Market Trend, 2021–2035
FIGURE 55: Hospitals and Academic Medical Centers Market Trend, 2021–2035
FIGURE 56: Retail Pharmacies, Specialty Pharmacies and DME Suppliers Market Trend, 2021–2035
FIGURE 57: Telehealth and Remote Diabetes Management Providers Market Trend, 2021–2035
FIGURE 58: Regional Segment Market Share Analysis, 2025 & 2035
FIGURE 59: Regional Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 60: Type 1 Diabetes Population and Device Adoption Analysis, by Region
FIGURE 61: Regional CGM and Automated Insulin Delivery Penetration Analysis
FIGURE 62: Regional Reimbursement and Device Access Opportunity Map
FIGURE 63: West Region U.S. Type 1 Diabetes Care Devices Market Share and Leading Players, 2025
FIGURE 64: West Region Market Share Analysis by State, 2025
FIGURE 65: West Region Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 66: California Type 1 Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 67: Washington Type 1 Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 68: Arizona Type 1 Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 69: Colorado Type 1 Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 70: Oregon Type 1 Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 71: Utah Type 1 Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 72: Nevada Type 1 Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 73: New Mexico Type 1 Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 74: Idaho Type 1 Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 75: Montana Type 1 Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 76: Wyoming Type 1 Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 77: Alaska Type 1 Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 78: Hawaii Type 1 Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 79: Northeast Region U.S. Type 1 Diabetes Care Devices Market Share and Leading Players, 2025
FIGURE 80: Northeast Region Market Share Analysis by State, 2025
FIGURE 81: Northeast Region Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 82: New York Type 1 Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 83: Massachusetts Type 1 Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 84: New Jersey Type 1 Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 85: Pennsylvania Type 1 Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 86: Connecticut Type 1 Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 87: Maine Type 1 Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 88: Vermont Type 1 Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 89: New Hampshire Type 1 Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 90: Rhode Island Type 1 Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 91: South Region U.S. Type 1 Diabetes Care Devices Market Share and Leading Players, 2025
FIGURE 92: South Region Market Share Analysis by State, 2025
FIGURE 93: South Region Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 94: Texas Type 1 Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 95: Florida Type 1 Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 96: Georgia Type 1 Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 97: North Carolina Type 1 Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 98: Tennessee Type 1 Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 99: South Carolina Type 1 Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 100: Alabama Type 1 Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 101: Mississippi Type 1 Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 102: Louisiana Type 1 Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 103: Arkansas Type 1 Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 104: Kentucky Type 1 Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 105: Oklahoma Type 1 Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 106: Virginia Type 1 Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 107: Maryland Type 1 Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 108: West Virginia Type 1 Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 109: Delaware Type 1 Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 110: District of Columbia Type 1 Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 111: Midwest Region U.S. Type 1 Diabetes Care Devices Market Share and Leading Players, 2025
FIGURE 112: Midwest Region Market Share Analysis by State, 2025
FIGURE 113: Midwest Region Market Size Forecast and Trend Analysis, 2021–2035
FIGURE 114: Illinois Type 1 Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 115: Ohio Type 1 Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 116: Michigan Type 1 Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 117: Minnesota Type 1 Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 118: Indiana Type 1 Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 119: Wisconsin Type 1 Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 120: Missouri Type 1 Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 121: Iowa Type 1 Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 122: Kansas Type 1 Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 123: Nebraska Type 1 Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 124: North Dakota Type 1 Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 125: South Dakota Type 1 Diabetes Care Devices Market Size, Forecast and Trend Analysis, 2021–2035
FIGURE 126: Competitive Landscape; Key Company Market Share Analysis, 2025
FIGURE 127: Company Positioning Matrix
FIGURE 128: Key Player Product Portfolio Benchmarking
FIGURE 129: CGM Installed-Base Competitive Benchmarking
FIGURE 130: Insulin Pump and Automated Insulin Delivery Installed-Base Benchmarking
FIGURE 131: Strategic Partnership and Interoperability Matrix
FIGURE 132: Strategic Developments, Partnerships, M&A and Product Launches
FIGURE 133: U.S. Type 1 Diabetes Care Device Innovation Roadmap
FIGURE 134: Automated Insulin Delivery Technology Roadmap
FIGURE 135: Extended-Wear and Implantable CGM Opportunity Map
FIGURE 136: Future Market Scenario Analysis, 2026–2035
FIGURE 137: Disruptive Technologies Impact Matrix
FIGURE 138: CGM Penetration Outlook Through 2035
FIGURE 139: Automated Insulin Delivery Penetration Outlook Through 2035
FIGURE 140: Multiple Daily Injection-to-Pump Conversion Opportunity
FIGURE 141: Pediatric Diabetes Technology Adoption Outlook
FIGURE 142: Medicare Type 1 Diabetes Technology Opportunity
FIGURE 143: Emerging Business Trends Matrix
FIGURE 144: Investment Prioritization Matrix
FIGURE 145: Strategic Growth Roadmap for U.S. Type 1 Diabetes Device Companies
FIGURE 146: U.S. Go-to-Market Strategy Framework
FIGURE 147: Product Positioning and Portfolio Expansion Framework
FIGURE 148: Payer Contracting and Reimbursement Strategy Framework
FIGURE 149: Interoperability Partnership Strategy Framework
FIGURE 150: Patient Retention and Recurring Revenue Strategy Framework
FIGURE 151: Report Scope and Disclaimer Framework